A Phase I, Single Center, Open-Label, Partially Randomized, Two Part Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute Bioavailability of Oral Capsule Formulations of GDC-9545 F12 and F18 and the Relative Bioavailability of F18 Compared to F12 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential
Phase: PHASE1
Conditions: Healthy Volunteers
Sponsor: Genentech, Inc.

 
 
CONFIDENTIAL 
The information contained in this document, especially any unpublished data, is the property of 
Genentech, Inc. (or under its control) and therefore is provided to you in confidence as an Investigator, 
potential Investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee 
or Institutional Review Board.  It is understood that this information will not be disclosed to others 
without written authorization from Genentech except to the extent necessary to obtain informed 
consent from persons to whom the drug may be administered. 
 
GDC-9545—Genentech, Inc. 
Protocol GP42662 (QSC204283), Version 4 
PROTOCOL 
TITLE: 
A PHASE I, SINGLE CENTER, OPEN-LABEL, 
PARTIALLY RANDOMIZED, TWO PART STUDY 
TO INVESTIGATE THE ABSORPTION, 
METABOLISM, AND EXCRETION OF 
[14C]-GDC-9545 FOLLOWING A SINGLE ORAL 
DOSE (PART 1) AND TO EVALUATE THE 
ABSOLUTE BIOAVAILABILITY OF ORAL 
CAPSULE FORMULATIONS OF GDC-9545 F12 
AND F18 AND THE RELATIVE BIOAVAILABILITY 
OF F18 COMPARED TO F12 (PART 2) IN 
HEALTHY FEMALE SUBJECTS OF 
NON-CHILDBEARING POTENTIAL 
PROTOCOL NUMBER: GP42662 (QSC204283) 
VERSION NUMBER: 
4 
EUDRACT NUMBER: 
2020-004650-29 
IND NUMBER: 
Not applicable 
NCT NUMBER: 
NCT04680273 
TEST PRODUCT: 
GDC-9545 (RO7197597) 
CLINICAL 
PHARMACOLOGY: 
MS, PharmD 
SPONSOR: 
Genentech, Inc. 
DATE FINAL: 
18 Feb 2021 

 
 
GDC-9545—Genentech, Inc. 
2/Protocol GP42662 (QSC204283), Version 4 
 
TABLE OF CONTENTS 
PROTOCOL ACCEPTANCE FORM .................................................................... 8 
PROTOCOL ACCEPTANCE FORM .................................................................... 9 
PROTOCOL SYNOPSIS .................................................................................... 10 
1. 
BACKGROUND .......................................................................................... 20 
1.1 
Background on Breast Cancer ............................................... 20 
1.2 
Background on GDC-9545 .................................................... 20 
1.2.1 
Toxicology and Safety Pharmacology ................................... 20 
1.2.2 
Clinical Summary ................................................................... 21 
1.2.2.1 
Safety .................................................................................... 22 
 
 23 
1.3 
Study Rationale and Benefit-Risk Assessment ...................... 26 
1.3.1 
Study Rationale ..................................................................... 27 
1.3.2 
Risk-Benefit Assessment ....................................................... 27 
2. 
OBJECTIVES AND ENDPOINTS ............................................................... 28 
2.1 
Mass Balance, Pharmacokinetic and Metabolite 
Profiling and Identification Objectives (Primary 
and Secondary Study Objectives) ......................................... 28 
2.1.1 
Part 1 ..................................................................................... 28 
2.1.2 
Part 2 ..................................................................................... 29 
2.2 
Safety Objective (Secondary Study Objective) ...................... 30 
3. 
STUDY DESIGN ......................................................................................... 30 
3.1 
Description of the Study......................................................... 30 
3.1.1 
Part 1 ..................................................................................... 30 
3.1.2 
Part 2 ..................................................................................... 32 
3.2 
End of Study and Length of Study ......................................... 34 
3.3 
Rationale for Study Design .................................................... 34 
3.3.1 
Rationale for Subject Population ........................................... 34 
3.3.2 
Rationale for [14C]-GDC-9545 and GDC-9545 
Doses and Schedule ............................................................. 36 
3.3.2.1 
Part 1 ..................................................................................... 36 
3.3.2.2 
Part 2 ..................................................................................... 37 

 
 
GDC-9545—Genentech, Inc. 
3/Protocol GP42662 (QSC204283), Version 4 
3.3.3 
Rationale for PK Sampling Schedule ..................................... 37 
4. 
MATERIALS AND METHODS .................................................................... 37 
4.1 
Subjects ................................................................................. 37 
4.1.1 
Inclusion Criteria .................................................................... 38 
4.1.2 
Exclusion Criteria ................................................................... 39 
4.2 
Method of Treatment Assignment and Blinding ..................... 41 
4.2.1 
Part 1 ..................................................................................... 41 
4.2.2 
Part 2 ..................................................................................... 41 
4.3 
Study Treatment and Other Treatments Relevant 
to the Study Design ............................................................... 42 
4.3.1 
Study Treatment Formulations and Packaging ...................... 42 
4.3.2 
Study Treatment Dosage, Administration, and 
Compliance ............................................................................ 43 
4.3.2.1 
[14C]-GDC-9545 and GDC-9545 ............................................ 43 
4.3.3 
Investigational Medicinal Product Handling and 
Accountability ........................................................................ 44 
4.3.3.1 
Retention of Study Drug Samples ......................................... 45 
4.4 
Concomitant Therapy, Prohibited Food, and 
Additional Restrictions ........................................................... 45 
4.4.1 
Permitted Therapy ................................................................. 45 
4.4.2 
Prohibited Therapy ................................................................ 45 
4.4.3 
Prohibited Food and Drink ..................................................... 46 
4.4.4 
Additional Restrictions ........................................................... 46 
4.5 
Study Assessments ............................................................... 47 
4.5.1 
Informed Consent Forms and Screening Log ........................ 47 
4.5.2 
Medical History, Baseline Conditions, 
Concomitant Medication, and Demographic Data ................. 48 
4.5.3 
Physical Examinations ........................................................... 48 
4.5.4 
Vital Signs .............................................................................. 49 
4.5.5 
Laboratory and Other Biological ............................................ 49 
4.5.5.1 
Safety Laboratory Assessments ............................................ 49 
4.5.5.2 
Mass Balance, Pharmacokinetic and Metabolite 
Profiling and Identification Assessments ............................... 50 
4.5.6 
Electrocardiograms ................................................................ 52 

 
 
GDC-9545—Genentech, Inc. 
4/Protocol GP42662 (QSC204283), Version 4 
4.6 
Treatment, Subject, Study, and Site 
Discontinuation ...................................................................... 53 
4.6.1 
Stopping Criteria .................................................................... 53 
4.6.2 
Subject Discontinuation from the Study ................................. 54 
4.6.3 
Study Discontinuation ............................................................ 55 
4.6.4 
Site Discontinuation ............................................................... 56 
5. 
ASSESSMENT OF SAFETY ....................................................................... 56 
5.1 
Safety Plan ............................................................................ 56 
5.1.1 
Risks Associated with GDC-9545 .......................................... 56 
5.1.2 
Risks Associated with Radiation ............................................ 57 
5.1.3 
COVID-19 Related Risks and Risk Mitigation 
Measures ............................................................................... 57 
5.1.3.1 
IMP-Related Risk ................................................................... 58 
5.1.3.2 
General COVID-19-Related Risk Mitigation 
Measures ............................................................................... 58 
5.1.4 
General Risks ........................................................................ 58 
5.2 
Safety Parameters and Definitions ........................................ 58 
5.2.1 
Adverse Events ..................................................................... 59 
5.2.2 
Serious Adverse Events (Immediately Reportable 
to the Sponsor) ...................................................................... 59 
5.2.3 
Adverse Events of Special Interest (Immediately 
Reportable to the Sponsor) .................................................... 60 
5.3 
Methods and Timing for Capturing and 
Assessing Safety Parameters ................................................ 61 
5.3.1 
Adverse Event Reporting Period ........................................... 61 
5.3.2 
Eliciting Adverse Event Information ....................................... 61 
5.3.3 
Assessment of Severity of Adverse Events ........................... 61 
5.3.4 
Assessment of Causality of Adverse Events ......................... 62 
5.3.5 
Procedures for Recording Adverse Events ............................ 63 
5.3.5.1 
Infusion-Related Reactions .................................................... 63 
5.3.5.2 
Diagnosis versus Signs and Symptoms................................. 63 
5.3.5.3 
Adverse Events That Are Secondary to Other 
Events.................................................................................... 64 
5.3.5.4 
Persistent or Recurrent Adverse Events ................................ 64 
5.3.5.5 
Abnormal Laboratory Values ................................................. 64 

 
 
GDC-9545—Genentech, Inc. 
5/Protocol GP42662 (QSC204283), Version 4 
5.3.5.6 
Abnormal Vital Sign Values ................................................... 65 
5.3.5.7 
Abnormal Liver Function Tests .............................................. 66 
5.3.5.8 
Deaths ................................................................................... 66 
5.3.5.9 
Preexisting Medical Conditions .............................................. 66 
5.3.5.10 
Hospitalization or Prolonged Hospitalization .......................... 67 
5.3.5.11 
Cases of Accidental Overdose or Medication 
Error....................................................................................... 67 
5.4 
Immediate Reporting Requirements from 
Investigator to Sponsor .......................................................... 68 
5.4.1 
Emergency Medical Contacts ................................................ 69 
5.4.2 
Reporting Requirements for Serious Adverse 
Events, Adverse Events of Special Interest ........................... 69 
5.4.2.1 
Events That Occur prior to Study Drug Initiation .................... 69 
5.4.2.2 
Events That Occur after Study Drug Initiation ........................ 70 
5.4.3 
Reporting Requirements for Pregnancies .............................. 70 
5.4.3.1 
Pregnancies in Female Subjects ........................................... 70 
5.4.3.2 
Abortions ............................................................................... 70 
5.4.3.3 
Congenital Anomalies/Birth Defects ...................................... 71 
5.5 
Follow-Up of Subjects after Adverse Events .......................... 71 
5.5.1 
Investigator Follow-Up ........................................................... 71 
5.5.2 
Sponsor Follow-Up ................................................................ 71 
5.6 
Adverse Events That Occur after the Adverse 
Event Reporting Period.......................................................... 71 
5.7 
Expedited Reporting to Health Authorities, 
Investigators, Institutional Review Boards, 
and Ethics Committees .......................................................... 72 
6. 
STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN ....................... 73 
6.1 
Determination of Sample Size ............................................... 73 
6.2 
Summaries of Conduct of Study ............................................ 74 
6.3 
Summaries of Demographic and Baseline 
Characteristics ....................................................................... 74 
6.4 
Mass Balance Analyses (Part 1 Only) ................................... 74 
6.5 
Pharmacokinetic Analyses ..................................................... 75 
6.6 
Metabolite Profiling and Identification Analyses ..................... 76 
6.7 
Safety Analyses ..................................................................... 76 

 
 
GDC-9545—Genentech, Inc. 
6/Protocol GP42662 (QSC204283), Version 4 
6.8 
Interim Analyses .................................................................... 77 
6.8.1 
Planned Interim Analysis ....................................................... 77 
7. 
DATA COLLECTION AND MANAGEMENT ............................................... 78 
7.1 
Data Quality Assurance ......................................................... 78 
7.2 
Electronic Case Report Forms ............................................... 78 
7.3 
Source Data Documentation .................................................. 79 
7.4 
Use of Computerized Systems .............................................. 79 
7.5 
Retention of Records ............................................................. 79 
8. 
ETHICAL CONSIDERATIONS .................................................................... 80 
8.1 
Compliance with Laws and Regulations ................................ 80 
8.2 
Informed Consent .................................................................. 80 
8.3 
Ethics Committee .................................................................. 81 
8.4 
Administration of Radiation .................................................... 82 
8.5 
Confidentiality ........................................................................ 82 
8.6 
Financial Disclosure .............................................................. 82 
9. 
STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION ..................................................................................... 83 
9.1 
Study Documentation ............................................................ 83 
9.2 
Protocol Deviations ................................................................ 83 
9.3 
Site Inspections ..................................................................... 83 
9.4 
Administrative Structure......................................................... 83 
9.5 
Dissemination of Data and Protection of Trade 
Secrets .................................................................................. 84 
9.6 
Protocol Amendments ........................................................... 85 
10. REFERENCES ........................................................................................... 86 
 
 
LIST OF TABLES 
 
 
 ...................................................................... 25 
 
 
 ...................................................................... 25 
 
 
 ...................................................................... 25 

 
 
GDC-9545—Genentech, Inc. 
7/Protocol GP42662 (QSC204283), Version 4 
Table 4 
Part 2 Treatment Sequences ...................................................... 41 
Table 5 
Adverse Event Severity Grading Scale for Events Not 
Specifically Listed in NCI CTCAE ............................................... 62 
Table 6 
Causal Attribution Guidance ....................................................... 63 
 
 
LIST OF FIGURES 
 
 
 ..................... 26 
 
 
 .................... 26 
Figure 3 
Overview of Part 1 Design .......................................................... 32 
Figure 4 
Overview of Part 2 Design .......................................................... 34 
 
 
LIST OF APPENDICES 
Appendix 1 
 Part 1 Schedule of Activities ...................................................... 87 
Appendix 2 
 Part 2 Schedule of Activities ...................................................... 92 
Appendix 3 
 Part 1 Schedule of Pharmacokinetic Samples ........................... 97 
Appendix 4 
 Part 2 Schedule of Pharmacokinetic Samples ......................... 103 

GDC-9545—Genentech, Inc. 
9/Protocol GP42662 (QSC204283), Version 4 
PROTOCOL ACCEPTANCE FORM 
TITLE: 
A PHASE I, SINGLE CENTER, OPEN-LABEL, 
PARTIALLY RANDOMIZED, TWO PART STUDY TO 
INVESTIGATE THE ABSORPTION, METABOLISM, 
AND EXCRETION OF [14C]-GDC-9545 FOLLOWING 
A SINGLE ORAL DOSE (PART 1) AND TO 
EVALUATE THE ABSOLUTE BIOAVAILABILITY OF 
ORAL CAPSULE FORMULATIONS OF GDC-9545 
F12 AND F18 AND THE RELATIVE 
BIOAVAILABILITY OF F18 COMPARED TO F12 
(PART 2) IN HEALTHY FEMALE SUBJECTS OF 
NON-CHILDBEARING POTENTIAL 
PROTOCOL NUMBER: GP42662 (QSC204283) 
VERSION NUMBER: 
4 
EUDRACT NUMBER: 
2020-004650-29 
IND NUMBER: 
Not applicable 
NCT NUMBER: 
NCT04680273 
TEST PRODUCT: 
GDC-9545 (RO7197597) 
CLINICAL 
PHARMACOLOGY: 
MS, PharmD 
SPONSOR: 
Genentech, Inc. 
I agree to conduct the study in accordance with the current protocol. 
MS, Pharm D, 
, 
 
 
 
 
 
 
 
 
Sponsor Representative’s Signature 
 
Date 
Please retain the signed original of this form for your study files.   
 
2/19/2021

 
GDC-9545—Genentech, Inc. 
10/Protocol GP42662 (QSC204283), Version 4 
PROTOCOL SYNOPSIS 
TITLE: 
A Phase I, Single Center, Open-Label, Partially Randomized, 
Two Part Study to Investigate the Absorption, Metabolism, and 
Excretion of [14C]-GDC-9545 following a Single Oral Dose 
(Part 1) and to Evaluate the Absolute Bioavailability of Oral 
Capsule Formulations of GDC-9545 F12 and F18 and the 
Relative Bioavailability of F18 Compared to F12 (Part 2) in 
Healthy Female Subjects of Non-childbearing Potential 
PROTOCOL NUMBER: 
GP42662 (QSC204283) 
VERSION NUMBER: 
4 
EUDRACT NUMBER: 
2020-004650-29 
IND NUMBER: 
Not applicable 
NCT NUMBER: 
NCT04680273 
TEST PRODUCT: 
GDC-9545 (RO7197597) 
PHASE: 
I 
INDICATION: 
Not applicable 
SPONSOR: 
Genentech, Inc. 
 
Objectives and Endpoints 
Part 1 of this study will evaluate the absorption, metabolism, excretion, pharmacokinetics and 
safety of GDC-9545 in healthy volunteers.  Part 2 of this study will evaluate the absolute and 
relative bioavailability, and safety of GDC-9545 in healthy volunteers.  Specific objectives and 
corresponding endpoints for the study are outlined below. 
 
Objectives 
Endpoints 
Primary 
Part 1: To determine the mass 
balance and routes of 
elimination of [14C]-GDC-9545 
following a single oral dose of 
[14C]-GDC-9545 capsule, 30 mg 
containing not more than (NMT) 
4.6 megabecquerel (MBq; 
124 microcurie [µCi]) 
Mass balance recovery of 
total radioactivity (TR) in all 
excreta (urine and feces): 
CumAe and CumFe 
Determination of routes 
and rates of elimination of 
[14C]-GDC-9545 by Ae, 
CumAe, Fe and CumFe by 
interval for all excreta 
(urine and feces) 
Part 1: To assess the 
pharmacokinetics (PK) of 
GDC-9545 and total drug-
derived material in plasma 
following a single oral dose of 
[14C]-GDC-9545 capsule, 30 mg 
(NMT 4.6 MBq [124 µCi]) 
Calculation of PK 
parameters as appropriate 
for GDC-9545 (plasma 
only) and TR (plasma and 
whole blood) 
Assessment of the 
concentrations of TR in 
whole blood and plasma  
Evaluation of whole 
blood:plasma 
concentration ratios for TR 

 
GDC-9545—Genentech, Inc. 
11/Protocol GP42662 (QSC204283), Version 4 
Part 2: To determine the 
absolute bioavailability of an 
oral GDC-9545/F12 capsule, 
30 mg and an oral 
GDC-9545/F18 capsule, 30 mg 
Absolute bioavailability 
assessment based on the 
PK parameter AUC0-inf for 
GDC-9545 
Part 2: To determine the 
relative bioavailability of 
GDC-9545/F18 capsule, 30 mg 
compared to the 
GDC-9545/F12 capsule, 30 mg 
Relative bioavailability 
assessment based on the 
PK parameters Cmax and 
AUC0-inf for GDC-9545 
Secondary 
Part 1: To characterize and 
identify metabolites of 
[14C]-GDC-9545 in plasma, 
urine, and feces 
Characterization of 
abundant metabolites by 
liquid chromatography-high 
resolution mass 
spectrometry 
Part 2: To characterize the PK 
of GDC-9545 following oral and 
intravenous (IV) administration 
Calculation of PK 
parameters as appropriate 
for GDC-9545 in plasma 
only 
Part 1 and Part 2: To evaluate 
the safety and tolerability of 
single doses of GDC-9545 
Incidence and severity of 
adverse events 
Incidence of abnormalities 
in laboratory safety tests, 
12-lead ECGs and vital 
sign measurements 
Metabolite profiling and identification will be reported separately from the Clinical Study Report 
as a standalone document. 
Study Design 
Description of Study 
This is an open-label, single-center, two part study in heathy female subjects of 
non-childbearing potential to investigate the absorption, metabolism, and excretion of 
[14C]-GDC-9545 (Part 1), the absolute bioavailability of formulations Roformis Number 
RO7197597/F12-01 (F12) and Roformis Number RO7197597/F18-01 (F18) (i.e., 
GDC-9545/F12 capsule, 30 mg and GDC-9545/F18 capsule, 30 mg), and relative bioavailability 
of GDC-9545 oral capsule F18 to the F12 formulation (Part 2). 
Part 1 
Part 1 is an open-label, single-treatment design.  It is planned to enroll 6 subjects to ensure data 
in a minimum of 4 evaluable subjects.  An evaluable subject for Part 1 of the study is defined as 
a subject who has provided mass balance and PK samples for up to 480 hours (up to Day 21) 
or until they have met the mass balance discharge criteria (i.e., cumulative recovery of 
radioactivity exceeds 90% of the administered dose; OR radioactivity in urine and feces is less 
than 1% of the administered dose over a 24 hour period on 2 consecutive PK sample collection 
days, as determined by quick counts). 
Each subject will receive a single oral dose of [14C]-GDC-9545 capsule, 30 mg (NMT 4.6 MBq 
[124 µCi]) with approximately 240 mL water in the fasted state (Treatment A). 
Subjects will undergo preliminary screening procedures for the study up to 28 days (Day -28 to 
Day -2) before [14C]-GDC-9545 administration on Day 1.  Subjects will be admitted in the 
morning on the day prior to [14C]-GDC-9545 administration (Day -1) and will be dosed in the 
morning of Day 1 following an overnight fast of a minimum of 10 hours.  
Urine and feces samples for measurement of TR will be collected pre-dose and at intervals until 
study completion including after discharge, if needed.  
Blood samples for measurement of plasma GDC-9545 and TR in plasma and whole blood will 
be collected pre-dose and at intervals until study completion including after discharge, if 
needed.  

 
GDC-9545—Genentech, Inc. 
12/Protocol GP42662 (QSC204283), Version 4 
Safety and tolerability will be monitored by clinical and laboratory assessments at intervals 
throughout the study. 
It is planned that subjects will remain resident in the clinical unit until 480 hours post-dose 
(Day 21) when they will be discharged from the clinical unit. 
Part 2 
Part 2 is a randomized, open-label, three-treatment, two-sequence crossover design conducted 
over three periods.  It is planned to enroll 10 subjects to ensure data in a minimum of 
8 evaluable subjects.  An evaluable subject for Part 2 of the study is defined as a subject who 
has received an investigational medicinal product (IMP) and has sufficient drug concentration 
measurements up to 168 hours after dosing for evaluation of defined PK parameters for each 
treatment, and have completed all planned safety assessments up to 168 hours after dosing for 
each treatment.  
Subjects will be randomly allocated to one of two treatment sequences (BCD and BDC). In each 
treatment period, subjects will receive a single 30 mg dose of GDC-9545 in the fasted state.  
GDC-9545 will be administered as one of three possible formulations according to the 
randomization schedule: 
• 
Treatment B: 30 mg GDC-9545 as a Solution for Infusion, 3 mg/mL administered 
intravenously in 10 mL as an infusion over 30 minutes 
• 
Treatment C: GDC-9545/F12 capsule, 30 mg, administered with approximately 240 mL 
water 
• 
Treatment D: GDC-9545/F18 capsule, 30 mg, administered with approximately 240 mL 
water 
Subjects will undergo preliminary screening procedures for the study up to 28 days (Day -28 to 
Day -2) before GDC-9545 administration on Day 1 of Period 1.  Subjects will be admitted in the 
morning on the day prior to the first GDC-9545 administration (Day -1 of Period 1).  Subjects will 
be resident in the clinical unit from the morning of Day -1 in Period 1 until Day 8 in Period 3 
(i.e., for 28 to 29 consecutive nights that will cover all 3 treatment periods).   
For each treatment period, subjects will be dosed in the morning of Day 1 following an overnight 
fast of a minimum of 10 hours. 
For Treatment B, to assess tolerability of the IV administration, the first subject will be dosed as 
a sentinel; then, at least 4 hours later, the second subject will be dosed only if there are no 
acute safety findings for the first subject. If the first two subjects tolerated the IV dose, in the 
opinion of the Principal Investigator and Medical Monitor, the remaining subjects will be dosed. 
The third subject will be dosed at least 20 hours after the second subject (i.e., at least 24 hours 
after the first subject). All subsequent dosing of the IV formulation will be staggered by at least 
15 minutes. 
Blood samples for measurement of plasma GDC-9545 will be collected pre-dose and at 
intervals until Day 8 of each period.  
Safety and tolerability will be monitored by clinical and laboratory assessments at intervals 
throughout the study. 
There will be a minimum washout of 10 days between each IMP administration and a follow-up 
call will take place 13 to 15 days post-final dose. 
Number of Subjects 
For Part 1, it is planned to enroll 6 subjects to ensure data in a minimum of 4 evaluable 
subjects.  For Part 2, it is planned to enroll 10 subjects to ensure data in a minimum of 
8 evaluable subjects.  No replacement subjects are to be used in Part 1 of this study.  Up to 
4 replacement subjects are permitted in Part 2 of this study to ensure there are 8 evaluable 
subjects. 
Target Population 
Inclusion Criteria 
Subjects must meet the following criteria for study entry: 
• 
Able and willing to comply with the study restrictions and to give written informed consent 
before any study procedure.   

 
GDC-9545—Genentech, Inc. 
13/Protocol GP42662 (QSC204283), Version 4 
• 
Healthy female subjects of non-childbearing potential that are non-pregnant, non-lactating 
females, who are either postmenopausal or surgically sterile, aged 30 to 65 years, inclusive, 
at time of signing Informed Consent Form (ICF) 
• 
Postmenopausal females are defined as: 
• 
Age >60 years; 
• 
Age ≤60 years and amenorrhea ≥12 months in the absence of chemotherapy, 
tamoxifen, toremifene, or ovarian suppression. Estradiol levels and/or 
follicle-stimulating hormone (FSH) levels in the postmenopausal range; 
• 
Surgically sterile females for at least 90 days prior to screening are defined as: 
• 
Bilateral salpingectomy; 
• 
Hysterectomy; 
• 
Bilateral oophorectomy; 
• 
For all subjects, the pregnancy test result must be negative at screening and admission 
(Day -1 for Part 1 and Day -1 of Period 1 for Part 2) 
• 
A body mass index (BMI) between 18.5 and 32.0 kg/m2, inclusive, at screening 
• 
Ability to comply with the study protocol 
• 
Must have regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per 
day) (Part 1 only) 
• 
Female subjects of non-childbearing potential do not need to use any methods of 
contraception.   
Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from study entry: 
• 
Women of childbearing potential, women who are pregnant or breastfeeding. 
• 
All women must have a negative highly sensitive serum pregnancy test result at 
screening and a negative highly sensitive urine pregnancy test at admission. 
• 
Subjects who have received any IMP in a clinical research study within the 90 days prior to 
Day 1 (Part 1) or Day 1 of Period 1 (Part 2) 
• 
History of serious adverse reaction or serious hypersensitivity to any drug or allergy to the 
study drug formulation excipients 
• 
Subjects who are, or are immediate family members of, a study site or Sponsor employee 
• 
Subjects who have previously been administered IMP in this study.  Subjects who have 
taken part in Part 1 are not permitted to take part in Part 2. 
• 
Evidence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; 
i.e., the virus that causes Coronavirus Disease 2019 [COVID-19]) infection 
• 
Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human 
immunodeficiency virus (HIV) antibody at screening 
• 
History of any drug or alcohol abuse in the past 2 years 
• 
Regular alcohol consumption >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 
40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type) 
• 
A confirmed positive alcohol breath test at screening or admission 
• 
Current smokers and those who have smoked within the last 12 months.  A confirmed 
breath carbon monoxide reading of greater than 10 ppm at screening or admission.  
• 
Current users of e-cigarettes and nicotine replacement products and those who have used 
these products within the last 12 months  
• 
Confirmed positive drugs of abuse test result at screening or admission 
• 
Radiation exposure, including that from the present study, excluding background radiation 
but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 
12 months or 10 mSv in the last 5 years.  No occupationally exposed worker, as defined in 
the Ionising Radiation Regulations 2017, shall participate in the study (Part 1 only) 

 
GDC-9545—Genentech, Inc. 
14/Protocol GP42662 (QSC204283), Version 4 
• 
Subjects who do not have suitable veins for multiple venipunctures/cannulation as 
assessed by the Investigator or delegate at screening 
• 
Clinically significant abnormal clinical chemistry, hematology, coagulation or urinalysis as 
judged by the Investigator.  Subjects with Gilbert’s Syndrome are allowed 
• 
Evidence of renal impairment at screening, as indicated by an estimated creatinine 
clearance (CLcr) of <70 mL/min using the Cockcroft-Gault equation  
• 
History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic 
respiratory or gastrointestinal (GI) disease (especially peptic ulceration, GI bleeding, 
ulcerative colitis, Crohn’s Disease or Irritable Bowel Syndrome), neurological or psychiatric 
disorder, as judged by the Investigator 
• 
Presence or history of clinically significant allergy requiring treatment, as judged by the 
Investigator.  Hay fever is allowed unless it is active 
• 
Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of 
blood 
• 
Subjects who are taking, or have taken, any medication (e.g., prescription drugs, 
over-the-counter drugs, hormone replacement therapy [HRT], vaccines, topical 
medications, herbal or homeopathic remedies, nutritional supplements), other than up to 4 g 
of paracetamol per day, in the 14 days before IMP administration.  Exceptions may apply on 
a case by case basis, if considered not to interfere with the objectives of the study, as 
determined by the Investigator. 
• 
Subjects who are taking, or have taken, oral antibiotics within 4 weeks or IV antibiotics 
within 8 weeks prior to admission. 
• 
Subjects who are taking, or have taken, any medications/products known to alter drug 
absorption, metabolism, or elimination processes, including St. John’s wort, within 30 days 
prior to admission. 
• 
History of GI surgery (with the exception of appendectomy unless it was performed within 
the previous 12 months) (Part 1 only) 
• 
Acute diarrhea or constipation in the 7 days before the predicted Day 1.  If screening 
occurs >7 days before the Day 1, this criterion will be determined on Day 1.  Diarrhea will 
be defined as the passage of liquid feces and/or a stool frequency of greater than 3 times 
per day.  Constipation will be defined as a failure to open the bowels for 3 days (Part 1 only) 
• 
Malabsorption syndrome or other condition that would interfere with enteral absorption 
• 
History or presence of an abnormal ECG that is clinically significant in the Investigator's 
opinion, including complete left bundle branch block, second- or third-degree 
atrioventricular heart block, or evidence of prior myocardial infarction 
• 
QT interval corrected through use of Fridericia's formula (QTcF)  440 msec demonstrated 
by at least two ECGs  30 minutes apart 
• 
History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as 
structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular 
hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by 
diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, 
hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT 
syndrome 
• 
Confirmed (e.g., 2 consecutive measurements) baseline heart rate ≤50 bpm prior to 
enrollment 
• 
Current treatment with medications that are well known to prolong the QT interval 
• 
Absolute neutrophil count <1.3  109/L (1300/L)  
• 
Failure to satisfy the Investigator of fitness to participate for any other reason 

 
GDC-9545—Genentech, Inc. 
15/Protocol GP42662 (QSC204283), Version 4 
End of Study 
The end of this study is defined as the date when the last subject, last visit (LSLV), occurs or 
the date at which the last data point required for statistical analysis (i.e., mass balance, PK 
and/or metabolite profiling and identification data for Part 1 and PK data for Part 2) or safety 
follow-up is received from the last subject, whichever occurs later.  The end of the study is 
expected to occur approximately 9 weeks after the last subject is enrolled in Part 2. 
Length of Study 
The total length of Part 1 of the study, from screening of the first subject to the end of the study, 
is expected to be approximately 10 weeks. The total length of Part 2 of the study, from 
screening of the first subject to the end of the study, is expected to be approximately 9 weeks. 
Investigational Medicinal Products 
Test Product (Investigational Drug) 
Part 1  
A single oral dose of [14C]-RO7197597 Capsule, 30 mg (NMT 4.6 MBq [124 µCi]), which is 
referred to as [14C]-GDC-9545 capsule in this protocol (Treatment A) 
Part 2  
A single dose of 30 mg GDC-9545 in each of three treatment periods; the following formulations 
will be administered: 
• 
Treatment B: RO7197597 Solution for Infusion, 3 mg/mL, (referred to as GDC-9545 
Solution for Infusion in this protocol) administered in a 10 mL volume intravenously over 
30 minutes (as an infusion) 
• 
Treatment C: Hard Capsules GDC-9545, 30 mg (referred to as GDC-9545/F12 capsule in 
this protocol), administered orally 
• 
Treatment D: Hard Capsules GDC-9545, 30 mg F18 (referred to as GDC-9545/F18 capsule 
in this protocol), administered orally 
Statistical Methods 
Primary Analysis 
Mass balance Analyses (Part 1 only) 
The following mass balance parameters will be calculated from urine and feces separately and 
total (urine and feces combined):  
• 
Aeu: amount of TR excreted in urine 
• 
CumAeu: cumulative amount of TR excreted in urine 
• 
Feu: amount of TR excreted in urine expressed as a percentage of the radioactive dose 
administered 
• 
CumFeu: cumulative amount of TR excreted in urine expressed as a percentage of the 
radioactive dose administered 
• 
Aef: amount of TR eliminated in feces 
• 
CumAef: cumulative amount of TR eliminated in feces 
• 
Fef: amount of TR eliminated in feces expressed as a percentage of the radioactive dose 
administered 
• 
CumFef: cumulative amount of TR eliminated in feces expressed as a percentage of the 
radioactive dose administered 
• 
Aetotal: amount of TR excreted in urine and feces combined 
• 
CumAetotal: cumulative amount of TR excreted in urine and feces combined 
• 
Fetotal: amount of TR excreted in urine and feces combined expressed as a percentage of 
the radioactive dose administered 
• 
CumFetotal: cumulative amount of TR excreted in urine and feces combined expressed as a 
percentage of the radioactive dose administered 

 
GDC-9545—Genentech, Inc. 
16/Protocol GP42662 (QSC204283), Version 4 
Pharmacokinetic Analyses 
The PK of GDC-9545 in plasma and TR in whole blood and plasma will be summarized by 
estimating the following parameters (as appropriate for data collected): 
• 
Cmax: maximum observed concentration 
• 
tmax: time of maximum observed concentration 
• 
AUC0-t: area under the curve from time 0 to the time of last measurable concentration 
• 
AUC0-inf: area under the curve from time 0 extrapolated to infinity 
• 
λZ: first order rate constant associated with the terminal (log-linear) portion of the curve 
• 
t1/2: terminal elimination half-life 
• 
CL: total body clearance calculated after a single IV administration (for GDC-9545 only; 
Part 2 IV dose only) 
• 
CL/F: total body clearance calculated after a single extravascular administration where F 
(fraction of dose bioavailable) is unknown (for GDC-9545 only; oral doses only) 
• 
Vz: volume of distribution based on the terminal phase calculated using AUC0-inf after a 
single IV administration (for GDC-9545 only; Part 2 IV dose only) 
• 
Vz/F: apparent volume of distribution (for GDC-9545 only; oral doses only) 
• 
Ratio between whole blood and plasma concentrations for TR (Part 1 only) 
• 
Ratio between whole blood and plasma AUC0-inf values for TR (Part 1 only) 
• 
F: Absolute bioavailability calculated using AUC0-inf (for GDC-9545 only; oral doses in Part 2 
only) 
• 
Frel Cmax: Relative bioavailability based on Cmax (for GDC-9545 only; GDC-9545/F18 
capsule, 30 mg in Part 2 only) 
• 
Frel AUC0-t: Relative bioavailability based on AUC0-t (for GDC-9545 only; GDC-9545/F18 
capsule, 30 mg in Part 2 only) 
• 
Frel AUC0-inf: Relative bioavailability based on AUC0-inf (for GDC-9545 only; GDC-9545/F18 
capsule, 30 mg in Part 2 only) 
The absolute bioavailability of GDC-9545/F12 capsule and GDC-9545/F18 capsule will be 
calculated using the AUC0-inf values obtained after oral and IV administration of GDC-9545. The 
mixed-effect analysis of variance model will be used for absolute bioavailability determination. 
The model will include formulation and period as fixed effects and a random subject effect. 
To evaluate the relative bioavailability of GDC-9545 as GDC-9545/F18 capsule compared to 
GDC-9545/F12 capsule, the PK parameters Cmax and AUC0-inf for GDC-9545 will be analyzed.  
The mixed-effect analysis of variance model for the two-period crossover design will be used for 
formulation comparison.  The model will include formulation and period as fixed effects and 
random subject effect (i.e., assuming a compound symmetry covariance structure).  
Log-transformed Cmax, AUC0-t, and AUC0-inf values will be evaluated to estimate ratios of 
geometric mean values and the corresponding 90% confidence intervals (CIs) (test: 
GDC-9545/F18 capsule, reference: GDC-9545/F12 capsule; or test: GDC-9545/F12 capsule, 
reference: GDC-9545 Solution for Infusion; or test: GDC-9545/F18 capsule, reference: 
GDC-9545 Solution for Infusion). 
Determination of Sample Size   
For Part 1, it is planned to enroll 6 subjects to ensure data in a minimum of 4 evaluable 
subjects.  For Part 2, it is planned to enroll 10 subjects to ensure data in a minimum of 
8 evaluable subjects.  No replacement subjects are to be used in Part 1 of this study.  Up to 
4 replacement subjects are permitted in Part 2 of this study to ensure there are 8 evaluable 
subjects. 
The study is exploratory, and no formal sample size calculation has been made.  Based on 
experience from previous studies of a similar design, a sample size of 6 subjects for Part 1 and 
10 subjects for Part 2 is considered appropriate to meet the objectives of the study. 
Interim Analyses 
No interim analyses are planned for Part 1.  

 
GDC-9545—Genentech, Inc. 
17/Protocol GP42662 (QSC204283), Version 4 
The following in-study decision will be made during Part 2 of this study: 
• 
Progression from sentinel group to main group where sentinel dosing is used for 
Treatment B 
For Treatment B, to assess tolerability of the IV administration, the first subject will be dosed as 
a sentinel; then, at least 4 hours later, the second subject will be dosed only if there are no 
acute safety findings for the first subject. If the first two subjects tolerated the IV dose, in the 
opinion of the Principal Investigator and Medical Monitor, the remaining subjects will be dosed. 
The third subject will be dosed at least 20 hours after the second subject (i.e., at least 24 hours 
after the first subject). All subsequent dosing of the IV formulation will be staggered by at least 
15 minutes. 
The decision to proceed with the main group will be made by the Investigator, based on safety 
data until up to 24 hours post-dose for the two sentinel subjects.  The Investigator will inform the 
sponsor of any safety concerns.  
The decision to proceed to the next dose level will be based on safety and tolerability data.  The 
following data are required: 
• 
Adverse events  
• 
ECGs 
• 
Vital signs 
 

 
GDC-9545—Genentech, Inc. 
18/Protocol GP42662 (QSC204283), Version 4 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation 
Definition 
14C 
carbon-14 
ALT 
alanine aminotransferase 
APTT 
activated partial thromboplastin time 
ARSAC 
Administration of Radioactive Substances Advisory 
Committee 
AST 
aspartate aminotransferase 
AUC 
area under the concentration-time curve 
BMI 
body mass index 
CI 
confidence interval 
CLcr 
creatinine clearance 
COVID-19 
Coronavirus Disease 2019 
CRO 
contract research organization 
CV% 
coefficient of variation 
EC 
Ethics Committee 
ECG 
electrocardiogram 
eCRF 
electronic Case Report Form 
EDC 
electronic data capture 
EMA 
European Medicines Agency 
ER 
estrogen receptor 
ESR1 
estrogen receptor 1 
FDA 
Food and Drug Administration 
F12 
Roformis Number RO7197597/F12-01 
F18 
Roformis Number RO7197597/F18-01 
FSH 
follicle stimulating hormone 
GCP 
Good Clinical Practice 
GGT 
gamma glutamyl transferase 
GI 
gastrointestinal 
HBsAg 
hepatitis B surface antigen 
HCV 
hepatitis C virus 
HER2 
human epidermal growth factor receptor 2 
HIV 
human immunodeficiency virus 
HRT 
hormone replacement therapy 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Council for Harmonisation 
IMP 
investigational medicinal product 

 
GDC-9545—Genentech, Inc. 
19/Protocol GP42662 (QSC204283), Version 4 
Abbreviation 
Definition 
IND 
Investigational New Drug (Application) 
INR 
international normalized ratio 
ISF 
Investigator Site File 
IV 
intravenous 
LBD 
ligand-binding domain 
LHRH 
luteinizing hormone-releasing hormone 
LSLV 
last subject, last visit 
MBq 
megabecquerel 
µCi 
microcurie 
MedDRA 
Medical Dictionary for Regulatory Activities 
MHRA 
Medicines and Healthcare products Regulatory Agency 
NCI CTCAE 
National Cancer Institute Common Terminology Criteria 
for Adverse Events 
NMT 
not more than 
PCR 
polymerase chain reaction 
PK 
pharmacokinetic(s) 
PLD 
phospholipidosis 
PT 
prothrombin time 
QTcF 
QT interval corrected through use of Fridericia's 
formula 
RBC 
red blood cell 
SAP 
Statistical Analysis Plan 
SARS-CoV-2 
severe acute respiratory syndrome coronavirus 2 
SUSAR 
suspected unexpected serious adverse reaction 
TR 
total radioactivity 
ULN 
upper limit of normal 
WBC 
white blood cell 

 
GDC-9545—Genentech, Inc. 
20/Protocol GP42662 (QSC204283), Version 4 
1. 
BACKGROUND 
1.1 
BACKGROUND ON BREAST CANCER 
Breast cancer is the most commonly diagnosed cancer in women, with an estimated 
global incidence of 2,088,849 new cases and 626,679 deaths reported in 2018 (Bray et 
al. 2018).  Approximately 80% of all breast cancers express estrogen receptor (ER) and 
the vast majority of these cancers are dependent on the ER for tumor growth and 
progression.  Modulation of estrogen activity and/or synthesis is the mainstay of 
therapeutic approaches in women with ER+ breast cancer.  However, despite the 
effectiveness of available endocrine therapies such as ER antagonists (e.g., tamoxifen), 
aromatase inhibitors (e.g., anastrozole, letrozole, and exemestane), and full ER 
antagonists/degraders (e.g., fulvestrant), many patients ultimately relapse or develop 
resistance to these agents and therefore require further treatment for optimal disease 
control. 
1.2 
BACKGROUND ON GDC-9545 
GDC-9545 (RO7197597) is a potent, orally bioavailable, small-molecule therapeutic 
agent that is being developed for the treatment of patients with ER+ breast cancer.  
GDC-9545 antagonizes the effects of estrogens via competitive binding to the 
ligand-binding domain (LBD) of both wild-type and mutant ER with nanomolar potency.  
Upon binding, GDC-9545 induces an inactive conformation to the ER LBD, as measured 
by displacement of co-activator peptides.  In addition to its direct antagonist properties, 
the mechanism of action of GDC-9545 includes reducing levels of ERα protein through 
proteasome-mediated degradation.  Degradation of ER is hypothesized to enable full 
suppression of ER signaling, which is not achieved by first generation ER therapeutics 
such as tamoxifen, which display partial agonism.  GDC-9545 potently inhibits the 
proliferation of multiple ER+ breast cancer cell lines in vitro, including cells engineered to 
express clinically relevant mutations in ER. 
GDC-9545 exhibited dose-dependent anti-tumor activity in xenograft models of ER+ 
breast cancer, including in a patient-derived xenograft model that harbors an estrogen 
receptor 1 (ESR1) mutation (ER.Y537S).  The efficacious dose range was 0.1 to 
10 mg/kg/day, and all doses were well tolerated.  Fulvestrant, when dosed according to 
a clinically relevant dosing scheme, was less efficacious than GDC-9545 in the 
assessed xenograft models.  Thus, GDC-9545 demonstrated robust nonclinical activity 
in ER+ breast cancer models of ESR1-wildtype- and ESR1-mutation-bearing disease. 
Refer to the GDC-9545 Investigator's Brochure (IB) for full details on nonclinical and 
clinical studies. 
1.2.1 
Toxicology and Safety Pharmacology 
Doses used in the pivotal 4- and 26-week toxicity studies were appropriate based on 
evidence of dose-limiting (monkeys) or potentially dose-limiting (rats) toxicities, and 
achievement of systemic exposures that are similar to or in excess of anticipated 

 
GDC-9545—Genentech, Inc. 
21/Protocol GP42662 (QSC204283), Version 4 
therapeutic exposures.  Adverse organ effects identified in both pivotal toxicity studies 
were dose-responsive, largely confined to the kidney and liver, and monitorable in the 
clinic using standard laboratory assessments.  Liver findings were partially to completely 
reversible, while nephropathy observed at 30 mg/kg in rats after 26 weeks of dosing did 
not reverse.  The findings in reproductive organs in both species are consistent with the 
anti-estrogenic mode of action of GDC-9545 and were partially reversible in both 
species.  
In both rats and monkeys, there was a dose-dependent phospholipidosis (PLD) 
observed in numerous organs, including in the retinal pigmented epithelium of the eye 
and choroid plexus epithelium at 30 mg/kg in rats.  In rats, PLD was not noted at 
3 mg/kg, but increased in incidence and severity with increasing dose.  In monkeys, 
dose-dependent PLD was present at all doses but was limited to minimal changes in the 
liver and lymph nodes at 7 mg/kg, the lowest dose tested.  In the 26-week chronic 
toxicity studies, the severity and incidence of PLD observed via light microscopy were 
reduced in some organs for both rats and monkeys suggesting partial reversibility in 
some organs after a 16-week recovery period. 
For the 26-week toxicity study in rats, dose levels of 3, 10, and 30 mg/kg/day resulted in 
area under the concentration-time curve (AUC)-based exposure factor that were 1x, 4x, 
and 13x relative to the 30 mg clinical dose with 30 mg/kg/day being considered the 
severely toxic dose for 10% of animals.  For the 26-week toxicity study in monkeys, dose 
levels of 7, 20, and 60 mg/kg/day resulted in AUC-based exposure factors that were 
0.4x, 0.9x, and 2.5x relative to the 30 mg clinical dose with 20 mg/kg/day being 
considered the highest non-severely toxic dose. 
GDC-9545 was not mutagenic in the bacterial mutagenesis assay, did not induce an 
increase in micronucleus formation in human lymphocytes in in vitro studies and was not 
phototoxic in an in vitro mammalian cell-based assay. 
Results from the nonclinical toxicity and safety pharmacology studies completed to date 
provide a robust characterization of the toxicity profile of GDC-9545 to support 
administration to patients with ER+ breast cancer in ongoing clinical trials. 
1.2.2 
Clinical Summary 
As of the data cutoff of 31 Jan 2020, GDC-9545 has been administered in two Phase I 
clinical studies, GO39932 and GO40987, and one clinical pharmacology trial, a relative 
bioavailability study, GP42006, is ongoing to evaluate the tablet and capsule 
formulations.  
Study GO39932 is a first-in-human Phase Ia/Ib, multicenter, open-label study evaluating 
the safety, pharmacokinetics (PK), and activity of GDC-9545 alone (at doses of 10 to 
250 mg) or in combination (doses of 100 mg GDC-9545) with palbociclib and/or 

 
GDC-9545—Genentech, Inc. 
22/Protocol GP42662 (QSC204283), Version 4 
luteinizing hormone-releasing hormone (LHRH) agonist in patients with ER+ (human 
epidermal growth factor receptor 2 [HER2]-) breast cancer.  
Study GO40987 is a Phase I, open-label, multicenter, preoperative study to assess 
changes in Ki67 levels and to evaluate the pharmacodynamics, PK, safety, and biologic 
activity of GDC-9545 in patients with Stage I to III operable ER+ (HER2-) untreated 
breast cancer. 
GDC-9545 administered at 30 mg once daily is also being evaluated in a Phase III trial in 
metastatic breast cancer in combination with palbociclib (BO41843; NCT04546009), in a 
Phase II trial in untreated ER+ HER2- early breast cancer, in combination with 
palbociclib (WO42133; NCT04436744) and in a Phase II trial in previously treated ER+ 
HER2- metastatic breast cancer (WO42312; NCT04576455). 
1.2.2.1 
Safety 
The single agent dose escalation portion of Study GO39932 enrolled 29 patients (dose 
levels of 10, 30, 90 and 250 mg).  No dose-limiting toxicities, serious adverse events, or 
adverse events of special interest were reported and a maximum tolerated dose was not 
determined.  Initially 100 mg and 250 mg (±LHRH agonist) GDC-9545 doses were 
chosen for single-agent dose expansion, and an escalation cohort combined 100 mg 
GDC-9545 with 125 mg palbociclib.  
 
 
 
 
.  Enrollment was completed for the 100 mg 
single agent expansion and 100 mg in combination with palbociclib expansion; at the 
time of the data cutoff (31 Jan 2020), enrollment was ongoing in the 30 mg GDC-9545 
expansion cohort. 
As of the data cutoff of 31 Jan 2020, within the dose escalation and dose expansion 
stages combined, a total of 87 patients have been treated with single-agent GDC-9545 
(±LHRH agonist) including 22 patients within the GDC-9545 30 mg cohort.  Forty-eight 
patients have been treated with 100 mg GDC-9545 in combination with 125 mg 
palbociclib (±LHRH agonist), and one patient participated in cardiac Cohort C1 (100 mg 
GDC-9545 in combination with 125 mg palbociclib). 
GDC-9545 is tolerated well as single−agent at all dose levels (10 mg to 250 mg) and in 
combination at 100 mg with palbociclib. 
Of the 87 patients treated with single-agent GDC-9545 at doses ranging from 10 to 
250 mg, regardless of attribution to study drug, adverse events occurring in 10% or more 
patients were: fatigue, back pain, nausea, arthralgia, cough, diarrhea, constipation, and 
pain in extremity.  Grade ≥3 adverse events irrespective of causality occurring in 2 or 
more patients were: diarrhea, decreased appetite, and fatigue. 

 
GDC-9545—Genentech, Inc. 
23/Protocol GP42662 (QSC204283), Version 4 
In the single agent cohorts, 7 patients (8%) experienced 8 serious events including: 
pleural effusion, pulmonary embolism, duodenal ulcer perforation, appendiceal abscess, 
small intestinal obstruction, fatigue, migraine, and paresthesia.  All serious adverse 
events were considered unrelated to GDC-9545 by the Investigators, except fatigue, 
which was also considered related to progressive disease.  One patient died due to a 
serious adverse event of duodenal ulcer perforation that was considered unrelated to 
GDC-9545 by the Investigator. 
Of the 48 patients treated with 100 mg GDC-9545 in combination with palbociclib, 
8 patients (17%) experienced 9 serious adverse events including: dyspnea, urinary tract 
infection, electrocardiogram QT prolonged, deep vein thrombosis, thrombocytopenia and 
fatal breast cancer progression (in one patient each), and neutropenia (3 patients); only 
Grade 3 QT prolonged was considered related to GDC-9545 by the Investigator. 
In Study GO40987, patients received GDC-9545 daily for approximately 14 days at one 
of three treatment cohorts (10, 30, and 100 mg).  
As of the data cutoff date of 31 Jan 2020, a total of 30 postmenopausal women with 
Stage I to III operable ER+ (HER2-) untreated breast cancer were treated with single-
agent GDC-9545 at doses ranging from 10 to 100 mg in Study GO40987.  Adverse 
events reported in ≥10% of patients irrespective of attribution to study drug were: 
nausea, procedural pain and hot flush, asthenia and arthralgia.  In this study, one patient 
experienced serious adverse event of breast abscess (Grade 3), following surgery, in the 
GDC-9545 10 mg dose group.  However, it was not related to study treatment.  No other 
Grade ≥3 adverse events or serious adverse events irrespective of causality, 
thromboembolic events, or issues with wound healing have been reported. 
Therefore, overall GDC-9545 was well tolerated at all dose levels in patients with early 
breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
  

 
GDC-9545—Genentech, Inc. 
24/Protocol GP42662 (QSC204283), Version 4 
 
 
 
 
 
 
 
  

 
GDC-9545—Genentech, Inc. 
25/Protocol GP42662 (QSC204283), Version 4 

 
GDC-9545—Genentech, Inc. 
26/Protocol GP42662 (QSC204283), Version 4 
1.3 
STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT 
The study population rationale and the dose rationale for the study drugs are discussed 
in Sections 3.3.1 and 3.3.2, respectively. 

 
GDC-9545—Genentech, Inc. 
27/Protocol GP42662 (QSC204283), Version 4 
1.3.1 
Study Rationale 
GDC-9545 is being investigated for the treatment of ER+ breast cancer, using a capsule 
formulation.  The efficacy of GDC-9545 is currently being assessed in breast cancer 
patients and as of the data cutoff of 31 Jan 2020, clinical benefit rate was reported in 
71 (60%) of 119 patients overall (in Study GO39932).  Additionally, GDC-9545 is being 
progressed into Phase III studies in metastatic breast cancer patients.   
To support the regulatory clinical pharmacology package for GDC-9545, a radiolabeled 
human mass-balance study (absorption, distribution, metabolism and elimination) is 
required to characterize the overall disposition and biotransformation of GDC-9545.  
Part 1 of this study is being conducted to investigate the mass balance recovery and 
metabolic profiling and identification for orally administered carbon-14 ([14C])-GDC-9545.  
The study will use oral administration to determine the metabolite profile of GDC-9545, 
as this is the intended therapeutic route. 
Part 2 of this study is being conducted to investigate the absolute and relative 
bioavailability of two GDC-9545 oral capsules, in order to aid formulation optimization for 
the development of a capsule formulation that will be successfully administered to 
patients. Formulation Roformis Number RO7197597/F12-01 (F12) is a 30 mg 
 capsule formulation manufactured using standard 
excipients and a 
. For Formulation Roformis Number 
RO7197597/F18-01 (F18), the encapsulation process of Formulation F12 was further 
improved and a 
 was selected as the manufacturing 
technology. 
 
1.3.2 
Risk-Benefit Assessment 
There will be no therapeutic benefit for the volunteers participating in the study.  The 
development of a product to improve the treatment of ER+ breast cancer will be of 
benefit to the wider community/patients with such symptoms. 
The risks of participation are primarily those associated with adverse reactions to the 
study drug, although there may also be some discomfort from collection of blood 
samples and other study procedures.  The tolerability profile of GDC-9545 from 
administration of single agent daily doses up to 250 mg to ER+ breast cancer patients 
has been characterized from previous clinical studies.  There have been few adverse 
drug reactions following GDC-9545 dosing in previous clinical studies in patients. With 
the exception of one event of fatigue (which was also considered related to progressive 
disease), no serious adverse drug reactions have been reported in the single agent 
studies. No specific safety concerns have been identified about the use of 30 mg 
GDC-9545 in healthy volunteers in this study.  
Because an intravenous (IV) dose of GDC-9545 has not been previously administered in 
a clinical study, a sentinel dosing design will be used for Treatment B in Part 2, i.e., the 

 
GDC-9545—Genentech, Inc. 
28/Protocol GP42662 (QSC204283), Version 4 
second subject administered Treatment B will be dosed at least 4 hours after the first 
subject, and the third subject will be dosed at least 20 hours after the second subject 
(i.e., at least 24 hours after the first subject). This will allow assessment of the tolerability 
of the IV administration in the first two subjects prior to dosing the remaining subjects. 
Potential risks identified in the IB include hepatotoxicity, venous thromboembolic events, 
renal dysfunction, bradycardia and QT prolongation, which will be monitored by safety 
laboratory and electrocardiogram (ECG) assessments as applicable.  Potential 
gastrointestinal (GI) toxicities will be monitored through adverse event monitoring.  
Potential drug-drug interactions with other medications are addressed by restrictions on 
concomitant medication use.  Potential risks to a developing fetus from GDC-9545 
exposure in utero, changes in female reproductive organs and menopausal symptoms 
and male/female infertility are addressed by exclusion of males and females of 
childbearing potential from this study. Risks associated with GDC-9545 are further 
discussed in Section 5.1.1. 
Risks associated with radiation and Coronavirus Disease 2019 (COVID-19) associated 
risks are discussed in Sections 5.1.2 and 5.1.3, respectively, and general risks 
associated with the conduct of the study are discussed in Section 5.1.4.  However, these 
risks are considered to be small and therefore acceptable. 
Overall, no significant safety concerns have been identified about the use of 30 mg 
GDC-9545 or [14C]-GDC-9545 in healthy volunteers.  All volunteers will be resident in the 
clinic and remain under medical supervision following study drug administration and will 
undergo a standard battery of safety assessments.  Hence, the risks to participants in 
this study are considered acceptable. 
2. 
OBJECTIVES AND ENDPOINTS 
Part 1 of this study will evaluate the absorption, metabolism, excretion, PK and safety of 
GDC-9545 in healthy volunteers.  Part 2 of this study will evaluate the absolute and 
relative bioavailability, and safety of GDC-9545 in healthy volunteers.  Specific 
objectives and corresponding endpoints for both parts of the study are outlined below.  
2.1 
MASS BALANCE, PHARMACOKINETIC AND METABOLITE 
PROFILING AND IDENTIFICATION OBJECTIVES (PRIMARY 
AND SECONDARY STUDY OBJECTIVES) 
2.1.1 
Part 1 
The primary mass balance and PK objectives for Part 1 of this study are as follows: 
• 
To determine the mass balance and routes of elimination of [14C]-GDC-9545 
following a single oral dose of [14C]-GDC-9545 capsule, 30 mg containing not more 
than (NMT) 4.6 megabecquerel (MBq; 124 microcurie [µCi]) on the basis of the 
following endpoints: 

 
GDC-9545—Genentech, Inc. 
29/Protocol GP42662 (QSC204283), Version 4 
– 
Mass balance recovery of total radioactivity (TR) in all excreta (urine and 
feces): CumAe and CumFe 
– 
Determination of routes and rates of elimination of [14C]-GDC-9545 by Ae, 
CumAe, Fe and CumFe by interval for all excreta (urine and feces) 
• 
To assess the PK of GDC-9545 and total drug-derived material in plasma following 
a single oral dose of [14C]-GDC-9545 capsule, 30 mg (NMT 4.6 MBq [124 µCi]) on 
the basis of the following endpoints: 
– 
Calculation of PK parameters as appropriate for GDC-9545 (plasma only) and 
TR (plasma and whole blood) 
– 
Assessment of the concentrations of TR in whole blood and plasma  
– 
Evaluation of whole blood:plasma concentration ratios for TR 
The secondary metabolite profiling and identification objective for Part 1 of this study is 
as follows: 
• 
To characterize and identify metabolites of [14C]-GDC-9545 in plasma, urine, and 
feces on the basis of the following endpoint: 
– 
Characterization of abundant metabolites by liquid chromatography-high 
resolution mass spectrometry 
Metabolite profiling and identification will be reported separately from the Clinical Study 
Report as a standalone document. 
 
2.1.2 
Part 2 
The primary PK objectives for Part 2 of this study are as follows: 
• 
To determine the absolute bioavailability of an oral GDC-9545/F12 capsule, 30 mg 
and an oral GDC-9545/F18 capsule, 30 mg on the basis of the following endpoints: 
– 
Absolute bioavailability assessment based on the PK parameter AUC0-inf for 
GDC-9545  
• 
To determine the relative bioavailability of GDC-9545/F18 capsule, 30 mg compared 
to the GDC-9545/F12 capsule, 30 mg on the basis of the following endpoint: 
– 
Relative bioavailability assessment based on the PK parameters Cmax and 
AUC0-inf for GDC-9545  
The secondary PK objectives for Part 2 of this study are as follows: 
• 
To characterize the PK of GDC-9545 following oral and IV administration on the 
basis of the following endpoint: 
– 
Calculation of PK parameters as appropriate for GDC-9545 in plasma only 
 

 
GDC-9545—Genentech, Inc. 
30/Protocol GP42662 (QSC204283), Version 4 
2.2 
SAFETY OBJECTIVE (SECONDARY STUDY OBJECTIVE) 
The safety (secondary) objective for both Parts 1 and 2 of this study is to evaluate the 
safety and tolerability of single doses of GDC-9545 on the basis of the following 
endpoints: 
• 
Incidence and severity of adverse events 
• 
Incidence of abnormalities in laboratory safety tests, 12-lead ECGs and vital sign 
measurements 
 
3. 
STUDY DESIGN 
3.1 
DESCRIPTION OF THE STUDY 
This is an open-label, single-center, two part study in heathy female subjects of 
non-childbearing potential to investigate the absorption, metabolism, and excretion of 
[14C]-GDC-9545 (Part 1), the absolute bioavailability of formulations F12 and F18 (i.e., 
GDC-9545/F12 capsule, 30 mg and GDC-9545/F18 capsule, 30 mg) and relative 
bioavailability of GDC-9545 oral capsule F18 to the F12 formulation (Part 2). 
Subjects who do not meet the criteria for participation in this study (screen failure) may 
qualify for 1 re-screening opportunity (for a total of 2 screenings per participant) at the 
Investigator's discretion.  Subjects must re-sign the consent form prior to re-screening.  
The Investigator will record reasons for screen failure in the screening log (see 
Section 4.5.1). 
It is planned that Part 1 will begin prior to Part 2 of the study, and that the two parts of 
the study will partially overlap. 
3.1.1 
Part 1 
Part 1 is an open-label, single-treatment design.  It is planned to enroll 6 subjects to 
ensure data in a minimum of 4 evaluable subjects.  An evaluable subject for Part 1 of the 
study is defined as a subject who has provided mass balance and PK samples for up to 
480 hours (up to Day 21) or until they have met the mass balance discharge criteria (i.e., 
cumulative recovery of radioactivity exceeds 90% of the administered dose; OR 
radioactivity in urine and feces is less than 1% of the administered dose over a 24 hour 
period on 2 consecutive PK sample collection days, as determined by quick counts). 
Each subject will receive a single oral dose of [14C]-GDC-9545 capsule, 30 mg (NMT 
4.6 MBq [124 µCi]) with approximately 240 mL water in the fasted state (Treatment A). 
Subjects will undergo preliminary screening procedures for the study up to 28 days 
(Day -28 to Day -2) before [14C]-GDC-9545 administration on Day 1.  Subjects will be 
admitted in the morning on the day prior to [14C]-GDC-9545 administration (Day -1) and 
will be dosed in the morning of Day 1 following an overnight fast of a minimum of 
10 hours.  

 
GDC-9545—Genentech, Inc. 
31/Protocol GP42662 (QSC204283), Version 4 
Urine and feces samples for measurement of TR will be collected pre-dose and at 
intervals until study completion including after discharge, if needed.  
Blood samples for measurement of plasma GDC-9545 and TR in plasma and whole 
blood will be collected pre-dose and at intervals until study completion including after 
discharge, if needed.  
Safety and tolerability will be monitored by clinical and laboratory assessments at 
intervals throughout the study. 
It is planned that subjects will remain resident in the clinical unit until 480 hours 
post-dose (Day 21) when they will be discharged from the clinical unit. 
It is planned that subjects will be released as a group when all subjects have achieved 
the following mass balance discharge criteria: 
• 
Cumulative recovery of radioactivity exceeds 90% of the administered dose; OR 
• 
Radioactivity in urine and feces is less than 1% of the administered dose over a 
24 hour period on 2 consecutive PK sample collection days, as determined by quick 
counts 
This may result in the subjects being discharged as a group prior to completion of the 
planned residency period.  Once the mass balance discharge criteria have been 
achieved, collection of all samples (blood, urine, and feces) may be stopped and the 
subjects will undergo discharge assessments.  If the mass balance discharge criteria 
have not been met by all subjects by Day 21, subjects will be discharged from the 
clinical unit and those who have not met the discharge criteria will return for outpatient 
visits every 7 days for a 24-hour sample collection interval (i.e., subjects will be resident 
in the clinical unit for 24 hours during each return visit) until the mass balance discharge 
criteria are met (the maximum number of 24-hour return visits will not exceed 3).  
Discharged subjects may be asked to return for these visits if samples are needed 
post-discharge, prior to study completion.  During the period of weekly collection, mass 
balance cumulative recovery will be estimated by means of interpolation. 
If additional residency is not considered appropriate or necessary, then home collections 
of urine and/or feces may be requested at the discretion of the Investigator for individual 
subjects. 
The total duration of Part 1 of the study for each enrolled subject (screening through to 
end of study) will be approximately 10 weeks, divided as follows: 
• 
Screening: up to 28 days before the first dose of study drug. 
• 
A single treatment period, with admission on Day -1 and discharge from the clinical 
unit on or before Day 21  

 
GDC-9545—Genentech, Inc. 
32/Protocol GP42662 (QSC204283), Version 4 
• 
If mass balance discharge criteria have not been met by Day 21: return visits every 
7 days for a 24-hour sample collection interval until the radioactivity recovery criteria 
are met (maximum number of 24-hour outpatient visits will not exceed 3). 
Discharged subjects may be asked to return for these visits if samples are needed 
post-discharge, prior to study completion.   
Figure 3 presents an overview of the study design for Part 1.  A schedule of activities is 
provided in Appendix 1. 
Figure 3 Overview of Part 1 Design 
Screening 
Day -28 to Day -2 
 
Admission 
Day -1 
 
Dose 
Day 1 
 
Discharge 
Day 21a  
a Subjects may be discharged as a group earlier if the mass balance discharge criteria have been 
achieved.  If the criteria have not been met by Day 21, subjects will be discharged from the 
clinical unit and those who have not met the discharge criteria will return for outpatient visits 
every 7 days for a 24-hour sample collection interval until the mass balance discharge criteria are 
met (the maximum number of 24-hour return visits will not exceed 3).  Discharged subjects may 
be asked to return for these visits if samples are needed post-discharge, prior to study 
completion.  If additional residency is not considered appropriate or necessary, then home 
collections of urine and/or feces may be requested at the discretion of the Investigator for 
individual subjects. 
 
3.1.2 
Part 2 
Part 2 is a randomized, open-label, three-treatment, two-sequence crossover design 
conducted over three periods.  It is planned to enroll 10 subjects to ensure data in a 
minimum of 8 evaluable subjects.  An evaluable subject for Part 2 of the study is defined 
as a subject who has received an investigational medicinal product (IMP) and has 
sufficient drug concentration measurements up to 168 hours after dosing for evaluation 
of defined PK parameters for each treatment, and have completed all planned safety 
assessments up to 168 hours after dosing for each treatment.  
Subjects will be randomly allocated to one of two treatment sequences (BCD and BDC; 
see Section 4.2.2). In each treatment period, subjects will receive a single 30 mg dose of 
GDC-9545 in the fasted state.  GDC-9545 will be administered as one of three possible 
formulations according to the randomization schedule: 
• 
Treatment B: 30 mg GDC-9545 as a Solution for Infusion, 3 mg/mL administered 
intravenously in 10 mL as an infusion over 30 minutes 

 
GDC-9545—Genentech, Inc. 
33/Protocol GP42662 (QSC204283), Version 4 
• 
Treatment C: GDC-9545/F12 capsule, 30 mg, administered with approximately 
240 mL water 
• 
Treatment D: GDC-9545/F18 capsule, 30 mg, administered with approximately 
240 mL water 
Subjects will undergo preliminary screening procedures for the study up to 28 days 
(Day -28 to Day -2) before GDC-9545 administration on Day 1 of Period 1.  Subjects will 
be admitted in the morning on the day prior to the first GDC-9545 administration (Day -1 
of Period 1).  Subjects will be resident in the clinical unit from the morning of Day -1 in 
Period 1 until Day 8 in Period 3 (i.e., for 28 to 29 consecutive nights that will cover all 
3 treatment periods). 
For each treatment period, subjects will be dosed in the morning of Day 1 following an 
overnight fast of a minimum of 10 hours. 
For Treatment B, to assess tolerability of the IV administration, the first subject will be 
dosed as a sentinel; then, at least 4 hours later, the second subject will be dosed only if 
there are no acute safety findings for the first subject. If the first two subjects tolerated 
the IV dose, in the opinion of the Principal Investigator and Medical Monitor per the 
criteria in Section 6.8.1, the remaining subjects will be dosed. The third subject will be 
dosed at least 20 hours after the second subject (i.e., at least 24 hours after the first 
subject). All subsequent dosing of the IV formulation will be staggered by at least 
15 minutes. 
Blood samples for measurement of plasma GDC-9545 will be collected pre-dose and at 
intervals until Day 8 of each period.  
Safety and tolerability will be monitored by clinical and laboratory assessments at 
intervals throughout the study. 
The total duration of Part 2 of the study for each enrolled subject (screening through to 
end of study) will be approximately 9 weeks, divided as follows: 
• 
Screening: up to 28 days before the first dose of study drug. 
• 
Three treatment periods, separated by a treatment-free washout so there are at 
least 10 days between each of the three study drug administrations.  
• 
Safety follow-up call: 13 to 15 days after the last dose of study drug. 
Figure 4 presents an overview of the study design for Part 2.  A schedule of activities is 
provided in Appendix 2. 

 
GDC-9545—Genentech, Inc. 
34/Protocol GP42662 (QSC204283), Version 4 
Figure 4 Overview of Part 2 Design 
Screening 
Day -28 to Day -2 
 
Admission 
Day -1 (Period 1 only) 
 
Dose 
Day 1 (Periods 1, 2 and 3)a 
 
Discharge 
Day 8 (Period 3 only) 
 
Follow-Up Call 
13 to 15 days post-final dose 
a Subjects will receive Treatments B, C and D in Periods 1, 2 and 3 in a randomized manner.  
There will be a minimum washout of 10 days between each IMP administration. 
 
3.2 
END OF STUDY AND LENGTH OF STUDY 
The end of this study is defined as the date when the last subject, last visit (LSLV), 
occurs or the date at which the last data point required for statistical analysis (i.e., mass 
balance, PK and/or metabolite profiling and identification data for Part 1 and PK data for 
Part 2) or safety follow-up is received from the last subject, whichever occurs later.  The 
end of the study is expected to occur approximately 9 weeks after the last subject is 
enrolled in Part 2. 
In addition, the Sponsor may decide to terminate the study at any time. 
The total length of Part 1 of the study, from screening of the first subject to the end of the 
study, is expected to be approximately 10 weeks. The total length of Part 2 of the study, 
from screening of the first subject to the end of the study, is expected to be 
approximately 9 weeks. 
3.3 
RATIONALE FOR STUDY DESIGN 
3.3.1 
Rationale for Subject Population 
Healthy volunteers, instead of a patient population, have been chosen for this study in 
order to safely assess the absorption, metabolism, excretion, PK and safety properties of 
GDC-9545.   
As this is a Phase I study assessing the absorption, metabolism, excretion, PK, relative 
bioavailability and safety of GDC-9545, the most relevant population is healthy 
volunteers, as recommended by the U.S. Food and Drug Administration (FDA, (2002) 
and the European Medicines Agency (EMA, 2010).  Subjects who are non-smokers 

 
GDC-9545—Genentech, Inc. 
35/Protocol GP42662 (QSC204283), Version 4 
without a history of alcohol or drug abuse or regular co-medication are proposed to avoid 
interaction on drug metabolism and to avoid non-compliance. 
The target patient population for GDC-9545 is female ER+ breast cancer patients; 
therefore, it is necessary to assess the absorption, metabolism, excretion, PK and safety 
properties of GDC-9545 in female subjects. Based on the anti-estrogenic 
pharmacological activity of GDC-9545, administration during pregnancy is expected to 
have an adverse effect and poses a risk to the human fetus, including birth defects and 
miscarriage.  Additionally, only female subjects are to be enrolled owing to there being 
no previous clinical information on safety in males. Therefore, only female subjects of 
non-childbearing potential will be allowed to participate in the study. 
We acknowledge the Administration of Radioactive Substances Advisory Committee 
(ARSAC) Notes for Guidance recommend that wherever possible, healthy subjects 
selected for research projects should be aged over 50 years (2020).  However, the 
current study is designed to generate data for supporting the investigation of the human 
absorption, metabolism and excretion of a drug, as well as generating samples for 
metabolite profiling and structural identification. 
There are two main reasons for generating these data within a clinical development 
program.  The first is to provide human metabolite data that can be used to interpret the 
metabolism profiles seen in the preclinical species employed in the longer term toxicity 
studies, to ensure that there is adequate toxicology coverage for the safe development 
of the drug in patients.  The second is to provide data to understand how the drug is 
processed in physiologically normal subjects, because understanding the routes of 
metabolism and elimination in a healthy population generates the appropriate data to 
guide the clinical pharmacology package required to fulfil the regulatory requirements of 
a New Drug Application.  
In order to address these two main aims of an absorption, metabolism and excretion 
study, investigation of the drug under development is required in a population with 
normal physiological function, as it is recognized that certain physiological processes 
e.g., renal function, deteriorate with age and therefore it is preferable to use as healthy 
population as possible, to mitigate against factors which may make interpretation of the 
data difficult.  Also, healthy subjects as a trial population are ideal since they have a 
relatively stable physiological, biochemical and hormonal status, which removes any 
disease-related variations and variations due to concomitant medications. 
Additionally, healthy volunteers are considered more suitable for this study than for the 
following reasons: 
• 
Patients would not be expected to derive clinically meaningful benefit from 
GDC-9545 in this study because of the short duration of treatment 

 
GDC-9545—Genentech, Inc. 
36/Protocol GP42662 (QSC204283), Version 4 
• 
Patients participating in this study would need to discontinue standard-of-care 
therapy so that the study could achieve its objective of assessing the absorption, 
metabolism, excretion, PK profile safety and tolerability of GDC-9545  
• 
Healthy volunteers are expected to have the best systemic reserve to respond to 
any unexpected reactions to GDC-9545, such as hypersensitivity reactions 
Based on the above considerations and target population, healthy female subjects of 
non-childbearing potential (i.e., surgically sterilized or post-menopausal), aged ≥30 and 
≤65 years are considered suitable for this study. 
3.3.2 
Rationale for [14C]-GDC-9545 and GDC-9545 Doses and 
Schedule 
The planned therapeutic dose for GDC-9545 (which is currently being evaluated in a 
Phase III trial in metastatic breast cancer patients) is 30 mg once daily; therefore, 30 mg 
is the chosen dose for both Parts 1 and 2 of this study.  Single doses of GDC-9545 up to 
250 mg have been administered in previous Phase I clinical studies (in ER+ breast 
cancer patients), and have been found to be well tolerated. 
GDC-9545 will be given in the fasted state in order to avoid the potential for a food 
effect. 
This is an open-label study, because the parameters (i.e., mass balance recovery of TR 
in urine and feces, TR concentrations in plasma and whole blood, and GDC-9545 
concentrations in plasma) on which the primary endpoints are based are considered to 
be objective measures. 
3.3.2.1 
Part 1 
In order to assess the absorption, metabolism and excretion of GDC-9545, a single oral 
dose of [14C]-GDC-9545 capsule, 30 mg [NMT 4.6 MBq [124 µCi]) in Part 1. 
The dose of radioactivity has been determined following review of nonclinical 
quantitative whole body autoradiography data and the consequential human dosimetry 
prediction.  The effective dose will be 0.7 millisievert (mSv) and will fall within 
International Commission on Radiological Protection (1992) Guidelines for Category IIa 
studies (0.1 to 1 mSv).  The dose of radioactivity will be no more than 4.6 MBq 
(124 µCi). 
To ensure that the [14C] drug product(s) does not exceed the limit for radioactive dose 
approved by ARSAC, the target specific activity of the drug substance will be set at 90% 
of 90% of the threshold radioactive dosing limit.  This will allow for tolerances in the 
manufacturing processes for both drug substance and drug product thereby providing 
continued assurance for compliance with the ARSAC approved limit for drug product 
radioactivity dose. 

 
GDC-9545—Genentech, Inc. 
37/Protocol GP42662 (QSC204283), Version 4 
3.3.2.2 
Part 2 
In order to assess the relative and absolute bioavailability of different oral formulations of 
GDC-9545, a single IV administration of 30 mg GDC-9545 as a Solution for Infusion, 
3 mg/mL will be administered (as an infusion) for Treatment B and single oral doses of 
capsule formulations F12 and F18 (i.e., GDC-9545/F12 capsule, 30 mg and 
GDC-9545/F18 capsule, 30 mg) will be administered for Treatments C and D, 
respectively. 
An IV dose of 30 mg was selected to be equal to the oral dose in order to prevent any 
difficulties in comparison of the IV and oral dose that may arise if there is non-linearity in 
the PK. Simulations for the IV dose of 30 mg in 10 mL infused over 30 minutes using the 
population PK model and the physiologically based PK model for GDC-9545 predicted 
peak concentrations that were within the range of concentrations observed previously in 
clinic (the highest Cmax observed previously being 1650 ng/mL at steady-state following 
administration of 250 mg GDC-9545 once daily). 
For Treatment B, to assess tolerability of the IV administration, the first subject will be 
dosed as a sentinel; then, at least 4 hours later, the second subject will be dosed only if 
there are no acute safety findings for the first subject. If the first two subjects tolerated 
the IV dose, in the opinion of the Principal Investigator and Medical Monitor per the 
criteria in Section 6.8.1, the remaining subjects will be dosed. The third subject will be 
dosed at least 20 hours after the second subject (i.e., at least 24 hours after the first 
subject). All subsequent dosing of the IV formulation will be staggered by at least 15 
minutes. 
A crossover design was chosen for Part 2 for Treatments C and D because it utilizes 
within-subject, as well as between-subject, comparisons and is consequently more 
efficient than a standard parallel group design.  As each subject acts as their own 
control, the impact of confounding factors is also minimized.  Subjects were randomized 
between treatment sequences BCD and BDC to minimize allocation and selection bias. 
3.3.3 
Rationale for PK Sampling Schedule  
The PK sampling schedule has been selected on the basis of data from previous studies 
in which single doses of GDC-9545 have been administered to patients.  The frequent 
sampling schedule that follows the single doses of GDC-9545 is designed to capture 
data at a sufficient number of time points to provide a detailed profile of the absorption, 
distribution, and elimination of this drug, including time to maximum observed 
concentration (tmax) and terminal half-life (t1/2). 
4. 
MATERIALS AND METHODS  
4.1 
SUBJECTS 
Approximately 16 (6 in Part 1 and 10 in Part 2) healthy female volunteers of 
non-childbearing potential will be enrolled at one investigative site located in the UK. 

 
GDC-9545—Genentech, Inc. 
38/Protocol GP42662 (QSC204283), Version 4 
No replacement subjects are to be used in Part 1 of this study.  Up to 4 replacement 
subjects are permitted in Part 2 of this study to ensure there are 8 evaluable subjects; a 
maximum of 6 subjects in Part 1 and 14 subjects in Part 2 may be dosed. 
Subjects will be recruited from the Quotient Sciences panel or by direct advertising to the 
public.  Quotient Sciences (the Clinical Research Unit) must have a full medical history 
from each subject’s General Practitioner as follows: 
• 
Within the last 24 months prior to enrollment in the study for all volunteers who have 
previously participated in a clinical research study at Quotient Sciences.  
• 
Within the last 12 months prior to enrollment in the study for all new volunteers. 
Before subjects are admitted to the clinic, The Over Volunteering Prevention System will 
be checked to ensure that each subject has not been dosed in a study within 90 days of 
the planned Day 1 (Part 1) or Day 1 of Period 1 (Part 2) of this study. 
4.1.1 
Inclusion Criteria 
Subjects must meet the following criteria for study entry: 
1. 
Able and willing to comply with the study restrictions and to give written informed 
consent before any study procedure.   
2. 
Healthy female subjects of non-childbearing potential that are non-pregnant, 
non-lactating females, who are either postmenopausal or surgically sterile, aged 
30 to 65 years, inclusive, at time of signing the Informed Consent Form (ICF) 
• 
Postmenopausal females are defined as: 
o Age >60 years; 
o Age ≤60 years and amenorrhea ≥12 months in the absence of 
chemotherapy, tamoxifen, toremifene, or ovarian suppression. Estradiol 
levels and/or follicle-stimulating hormone (FSH) levels in the 
postmenopausal range; 
• 
Surgically sterile females for at least 90 days prior to screening are defined as: 
o Bilateral salpingectomy; 
o Hysterectomy; 
o Bilateral oophorectomy; 
• 
For all subjects, the pregnancy test result must be negative at screening and 
admission (Day -1 for Part 1 and Day -1 of Period 1 for Part 2) 
3. 
A body mass index (BMI) between 18.5 and 32.0 kg/m2, inclusive, at screening 
4. 
Ability to comply with the study protocol 
5. 
Must have regular bowel movements (i.e., average stool production of ≥1 and ≤3 
stools per day) (Part 1 only) 

 
GDC-9545—Genentech, Inc. 
39/Protocol GP42662 (QSC204283), Version 4 
• 
Female subjects of non-childbearing potential do not need to use any methods of 
contraception.   
For both study parts, inclusion criterion 2 from the list above will be re-assessed at 
admission/pre-dose of Part 1 and admission/pre-dose of Part 2 Period 1. 
 
4.1.2 
Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from study entry: 
1. 
Women of childbearing potential, women who are pregnant or breastfeeding. 
– 
All women must have a negative highly sensitive serum pregnancy test result at 
screening and a negative highly sensitive urine pregnancy test at admission. 
2. 
Subjects who have received any IMP in a clinical research study within the 90 days 
prior to Day 1 (Part 1) or Day 1 of Period 1 (Part 2) 
3. 
History of serious adverse reaction or serious hypersensitivity to any drug or allergy 
to the study drug formulation excipients 
4. 
Subjects who are, or are immediate family members of, a study site or Sponsor 
employee 
5. 
Subjects who have previously been administered IMP in this study.  Subjects who 
have taken part in Part 1 are not permitted to take part in Part 2. 
6. 
Evidence of current severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2; i.e., the virus that causes COVID-19) infection 
7. 
Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or 
human immunodeficiency virus (HIV) antibody at screening 
8. 
History of any drug or alcohol abuse in the past 2 years 
9. 
Regular alcohol consumption >14 units per week (1 unit = ½ pint beer, or a 25 mL 
shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type) 
10. A confirmed positive alcohol breath test at screening or admission 
11. Current smokers and those who have smoked within the last 12 months.  A 
confirmed breath carbon monoxide reading of greater than 10 ppm at screening or 
admission.  
12. Current users of e-cigarettes and nicotine replacement products and those who 
have used these products within the last 12 months  
13. Confirmed positive drugs of abuse test result at screening or admission 
14. Radiation exposure, including that from the present study, excluding background 
radiation but including diagnostic x-rays and other medical exposures, exceeding 
5 mSv in the last 12 months or 10 mSv in the last 5 years.  No occupationally 
exposed worker, as defined in the Ionising Radiation Regulations 2017, shall 
participate in the study (Part 1 only) 
15. Subjects who do not have suitable veins for multiple venipunctures/cannulation as 
assessed by the Investigator or delegate at screening 

 
GDC-9545—Genentech, Inc. 
40/Protocol GP42662 (QSC204283), Version 4 
16. Clinically significant abnormal clinical chemistry, hematology, coagulation or 
urinalysis as judged by the Investigator (laboratory parameters are listed in 
Appendices 1 and 2).  Subjects with Gilbert’s Syndrome are allowed 
17. Evidence of renal impairment at screening, as indicated by an estimated creatinine 
clearance (CLcr) of <70 mL/min using the Cockcroft-Gault equation  
18. History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic 
respiratory or GI disease (especially peptic ulceration, GI bleeding, ulcerative colitis, 
Crohn’s Disease or Irritable Bowel Syndrome), neurological or psychiatric disorder, 
as judged by the Investigator 
19. Presence or history of clinically significant allergy requiring treatment, as judged by 
the Investigator.  Hay fever is allowed unless it is active 
20. Donation of blood or plasma within the previous 3 months or loss of greater than 
400 mL of blood 
21. Subjects who are taking, or have taken, any medication (e.g., prescription drugs, 
over-the-counter drugs, hormone replacement therapy [HRT], vaccines, topical 
medications, herbal or homeopathic remedies, nutritional supplements), other than 
up to 4 g of paracetamol per day, in the 14 days before IMP administration.  
Exceptions may apply on a case by case basis, if considered not to interfere with 
the objectives of the study, as determined by the Investigator. 
22. Subjects who are taking, or have taken, oral antibiotics within 4 weeks or IV 
antibiotics within 8 weeks prior to admission. 
23. Subjects who are taking, or have taken, any medications/products known to alter 
drug absorption, metabolism, or elimination processes, including St. John’s wort, 
within 30 days prior to admission. 
24. History of GI surgery (with the exception of appendectomy unless it was performed 
within the previous 12 months) (Part 1 only) 
25. Acute diarrhea or constipation in the 7 days before the predicted Day 1.  If screening 
occurs >7 days before the Day 1, this criterion will be determined on Day 1.  
Diarrhea will be defined as the passage of liquid feces and/or a stool frequency of 
greater than 3 times per day.  Constipation will be defined as a failure to open the 
bowels for 3 days (Part 1 only) 
26. Malabsorption syndrome or other condition that would interfere with 
enteral absorption 
27. History or presence of an abnormal ECG that is clinically significant in the 
Investigator's opinion, including complete left bundle branch block, second- or 
third-degree atrioventricular heart block, or evidence of prior myocardial infarction 
28. QT interval corrected through use of Fridericia's formula (QTcF)  440 msec 
demonstrated by at least two ECGs  30 minutes apart 
29. History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such 
as structural heart disease (e.g., severe left ventricular systolic dysfunction, left 
ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia 
demonstrated by diagnostic testing), clinically significant electrolyte abnormalities 

 
GDC-9545—Genentech, Inc. 
41/Protocol GP42662 (QSC204283), Version 4 
(e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden 
unexplained death or long QT syndrome 
30. Confirmed (e.g., 2 consecutive measurements) baseline heart rate ≤50 bpm prior to 
enrollment 
31. Current treatment with medications that are well known to prolong the QT interval 
32. Absolute neutrophil count <1.3  109/L (1300/L)  
33. Failure to satisfy the Investigator of fitness to participate for any other reason 
For Part 1, exclusion criteria 1, 6, 10, 11, 13, 16, 20, 21, 25, 27, 28, 29, 30, 31, 32 and 
33 from the list above will be re-assessed at admission/pre-dose. 
For Part 2, exclusion criteria 1, 6, 10, 11, 13, 16, 20, 21, 27, 28, 29, 30, 31, 32 and 33 
from the list above will be re-assessed at admission/pre-dose in Period 1. 
4.2 
METHOD OF TREATMENT ASSIGNMENT AND BLINDING  
This study is open-label; no blinding is required. 
4.2.1 
Part 1 
Part 1 is non-randomized; therefore, a randomization schedule will not be produced.  A 
treatment allocation will be produced prior to dosing with IMP, which will dictate the order 
in which each subject is administered the treatment.  The treatment allocation will be 
retained in the Investigator Site File (ISF). 
Eligible subjects will be assigned a unique identification number on the morning of 
dosing (Day 1) according to the code 
 to 
 for Part 1, using the lowest number 
available. 
4.2.2 
Part 2 
Using a computer-generated randomization schedule, subject numbers will be allocated 
to one of two treatment sequences (Table 4) in Part 2.  The allocation will be balanced 
with 5 subjects assigned to each of the treatment sequences. 
Table 4 
Part 2 Treatment Sequences 
Treatment Sequence 
Period 1 
Period 2 
Period 3 
BCD 
Treatment B 
Treatment C 
Treatment D 
BDC 
Treatment B 
Treatment D 
Treatment C 
B; Treatment B = 30 mg GDC-9545 as a Solution for Infusion, 3 mg/mL administered 
intravenously in 10 mL as an infusion over 30 minutes 
C; Treatment C = GDC-9545/F12 capsule, 30 mg, administered with approximately 240 mL water 
D; Treatment D = GDC-9545/F18 capsule, 30 mg, administered with approximately 240 mL water 
 
Eligible subjects will be assigned a unique identification number on the morning of 
dosing in Period 1 according to the code 
 to 
 for Part 2, using the lowest number 

 
GDC-9545—Genentech, Inc. 
42/Protocol GP42662 (QSC204283), Version 4 
available.  Replacement subjects will be allocated subject numbers 
 to 
, where 
the last 2 digits are the same as those of the original subject (e.g., if Subject 
 
withdraws the replacement will have Subject Number 
).  Replacement subjects will 
be assigned to the same treatment sequence as the subject they replaced and will 
receive any treatments that the replaced subject did not receive in addition to any 
treatments that are required to make the required comparison of interest. 
A treatment allocation list will be produced prior to dosing using the randomization 
schedule and will be retained in the ISF. 
The original randomization schedule and proof of quality control procedures will be held 
by the Data Sciences department at Quotient Sciences until the study is archived, at 
which time the randomization materials will be retained in the ISF. 
4.3 
STUDY TREATMENT AND OTHER TREATMENTS RELEVANT 
TO THE STUDY DESIGN 
The IMP for Part 1 of this study is: 
• 
For Treatment A: [14C]-RO7197597 Capsule, 30 mg (NMT 4.6 MBq [124 µCi]), which 
is referred to as [14C]-GDC-9545 capsule in this protocol 
The IMPs for Part 2 of this study are:  
• 
For Treatment B: RO7197597 Solution for Infusion, 3 mg/mL, (referred to as 
GDC-9545 Solution for Infusion in this protocol) 
• 
For Treatment C: Hard Capsules GDC-9545, 30 mg (referred to as GDC-9545/F12 
capsule in this protocol) 
• 
For Treatment D: Hard Capsules GDC-9545, 30 mg F18 (referred to as 
GDC-9545/F18 capsule in this protocol) 
4.3.1 
Study Treatment Formulations and Packaging 
For Part 1, the [14C]-GDC-9545 will be supplied by Pharmaron UK Ltd, Rushden, 
Northamptonshire, UK (Pharmaron) as a powder. 
For Part 2, the GDC-9545 active pharmaceutical ingredient will be supplied by the 
Sponsor.   
In Part 1, the radiolabeled Treatment A, [14C]-GDC-9545 capsule, 30 mg (NMT 4.6 MBq 
[124 µCi]), will be manufactured by Quotient Sciences as capsules for oral 
administration.  
In Part 2, two oral capsule formulations will be investigated (GDC-9545/F12 capsule, 
30 mg and GDC-9545/F18 capsule, 30 mg); both formulations will be manufactured by 
the Sponsor and will be supplied as 30 mg capsules. 

 
GDC-9545—Genentech, Inc. 
43/Protocol GP42662 (QSC204283), Version 4 
In Part 2, for the purposes of assessment of the absolute bioavailability of the oral 
formulations, an IV formulation (GDC-9545 as a Solution for Infusion, 3 mg/mL) will also 
be administered; this will be manufactured by Quotient Sciences. 
For information on the formulation and handling of [14C]-GDC-9545 and GDC-
9545, see the Investigational Medicinal Product Dossier. 
4.3.2 
Study Treatment Dosage, Administration, and Compliance 
The treatment regimens are summarized in Sections 3.1.1 and 3.1.2 for Parts 1 and 2 of 
the study, respectively. 
Refer to the dosing instructions for detailed instructions on drug preparation, storage, 
and administration. 
Details on treatment administration (e.g., dose and timing) should be noted on the 
Study Drug Administration electronic Case Report Form (eCRF).  Cases of accidental 
overdose or medication error, along with any associated adverse events, should be 
reported as described in Section 5.3.5.11. 
Guidelines for treatment interruption or discontinuation for subjects who experience 
adverse events are provided in Section 4.6. 
4.3.2.1 
[14C]-GDC-9545 and GDC-9545 
In Part 1, each subject will receive a single oral dose of [14C]-GDC-9545 capsule, 30 mg 
(NMT 4.6 MBq [124 µCi]) (Treatment A).  The test formulation will be swallowed whole 
with approximately 240 mL water following an overnight fast of a minimum of 10 hours. 
In Part 2, each subject will be randomized to receive a single dose of 30 mg GDC-9545 
in each of three treatment periods; the following formulations will be administered: 
• 
Treatment B: GDC-9545 Solution for Infusion, 3 mg/mL  
• 
Treatment C: GDC-9545/F12 capsule, 30 mg  
• 
Treatment D: GDC-9545/F18 capsule, 30 mg   
Treatment B will be administered in a 10 mL volume intravenously over 30 minutes (as 
an infusion) following an overnight fast of a minimum of 10 hours. 
To assess tolerability of the IV administration, the first subject will be dosed as a 
sentinel; then, at least 4 hours later, the second subject will be dosed only if there are no 
acute safety findings for the first subject. If the first two subjects tolerated the IV dose, in 
the opinion of the Principal Investigator and Medical Monitor per the criteria in 
Section 6.8.1, the remaining subjects will be dosed. The third subject will be dosed at 
least 20 hours after the second subject (i.e., at least 24 hours after the first subject). All 
subsequent dosing of the IV formulation will be staggered by at least 15 minutes. To 
allow for potential interruptions and pump variations, up to a 10% difference in duration 

 
GDC-9545—Genentech, Inc. 
44/Protocol GP42662 (QSC204283), Version 4 
of the IV administration will not be considered as a protocol deviation provided that the 
full planned dose is administered as these minor discrepancies should not have a 
significant impact on the overall study objectives.  
The planned administration time will be 30 minutes; the actual IV administration start and 
stop time will be recorded in the source.  
• 
The IV administration will finish within ± 3 minutes of the nominal time point 
Treatments C and D will be swallowed whole with approximately 240 mL water following 
an overnight fast of a minimum of 10 hours. 
There will be a minimum washout of 10 days between each IMP administration. 
[14C]-GDC-9545 and GDC-9545 doses are expressed as the free base equivalent. 
4.3.3 
Investigational Medicinal Product Handling and Accountability 
Quotient Sciences will manufacture the [14C]-GDC-9545 capsules and the GDC-9545 
Solution for Infusion.  The Sponsor will manufacture the GDC-9545/F12 and 
GDC-9545/F18 capsules.  The study site (i.e., Investigator or other authorized personnel 
[e.g., pharmacist]) is responsible for maintaining records of IMP delivery to the site, IMP 
inventory at the site, IMP use by each subject, and disposition or return of unused IMP, 
thus enabling reconciliation of all IMP received, and for ensuring that subjects are 
provided with doses specified by the protocol. 
The study site should follow all instructions included with each shipment of GDC-9545 
capsules.  The study site will acknowledge receipt of GDC-9545 capsules supplied by 
the Sponsor to confirm the shipment condition and content.  Any damaged shipments 
will be replaced.  The Investigator or designee must confirm that appropriate 
temperature conditions have been maintained during transit for all IMPs received and 
that any discrepancies have been reported and resolved before use of the IMPs.  All 
IMPs must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions, with access limited 
to the Investigator and authorized staff. 
Only subjects enrolled in the study may receive IMPs, and only authorized staff may 
supply or administer IMPs. 
IMPs will either be disposed of at the study site according to the study site's institutional 
standard operating procedure or be returned to the Sponsor with the appropriate 
documentation.  The site's method of destroying Sponsor-supplied IMPs must be agreed 
to by the Sponsor.  The site must obtain written authorization from the Sponsor before 
any Sponsor-supplied IMP is destroyed, and IMP destruction must be documented on 
the appropriate form. 

 
GDC-9545—Genentech, Inc. 
45/Protocol GP42662 (QSC204283), Version 4 
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by 
the study site should be recorded on the drug accountability log. 
Refer to the Pharmaceutical Development and Control Strategy Report, dosing 
instructions and/or the GDC-9545 IB for information on IMP handling, including 
preparation and storage, and accountability.  
4.3.3.1 
Retention of Study Drug Samples 
According to Title 21, Part 320 of the U.S. Code of Federal Regulations, reserve 
samples of the clinical supplies used in a bioavailability or bioequivalence study must be 
retained by the organization that conducted the study and stored under conditions that 
will maintain the integrity, identity, strength, quality and purity of the samples.  The 
samples for retention will be randomly selected by the Investigator or by a representative 
of the Investigator.  All samples must be retained at the study site for a period of at least 
5 years following the date on which the application or supplemental application is 
approved by the U.S. FDA.  If such application is not approved, all samples must be 
retained for at least 5 years following the date of completion of any bioavailability or 
bioequivalence study from which the reserve samples were obtained. 
4.4 
CONCOMITANT THERAPY, PROHIBITED FOOD, AND 
ADDITIONAL RESTRICTIONS 
Concomitant therapy consists of any medication (e.g., prescription drugs, 
over-the-counter drugs, HRT, vaccines, topical medications, herbal or homeopathic 
remedies, nutritional supplements) used by a subject in addition to protocol-mandated 
treatment from 14 days before IMP administration until discharge from the study.   
All such medications should be reported to the Investigator and recorded on the 
Concomitant Medications eCRF. 
4.4.1 
Permitted Therapy  
Subjects are permitted to use the following therapies during the study: 
• 
Up to 4 g of paracetamol per day  
• 
Medications to treat adverse events 
If any medication is required, the name, strength, frequency of dosing and reason for its 
use will be documented in the subject's source data. 
 
4.4.2 
Prohibited Therapy 
Subjects should not take any medication (e.g., prescription drugs, over the counter 
drugs, HRT, vaccines, topical medications, herbal or homeopathic remedies, nutritional 
supplements), with the exception of up to 4 grams of paracetamol per day, from 14 days 
before IMP administration until discharge from the study unless the Investigator has 
given prior consent.  The following categories of medication are specifically prohibited:  

 
GDC-9545—Genentech, Inc. 
46/Protocol GP42662 (QSC204283), Version 4 
• 
Investigational therapy (other than protocol-mandated study treatment) is prohibited 
within 90 days prior to initiation of study treatment and during study treatment. 
• 
Subjects may not take oral antibiotics within 4 weeks or IV antibiotics within 8 weeks 
prior to admission until discharge from the study, with the exception of any 
medications that are required to treat adverse events. 
• 
Subjects will not have received any medications/products known to alter drug 
absorption, metabolism, or elimination processes, including St. John’s wort, within 
30 days prior to admission until discharge from the study. 
 
4.4.3 
Prohibited Food and Drink  
Use of the following foods and drinks is prohibited as described below: 
• 
Consumption of liquids or foods containing grapefruit, cranberry, caffeine or other 
xanthines from 24 hours prior to admission until discharge from the clinical unit. 
• 
Consumption of food containing poppy seeds for 48 hours prior to screening and for 
48 hours prior to admission until discharge from the clinical unit. 
 
4.4.4 
Additional Restrictions  
For Part 1, subjects must not consume anything likely to disturb GI transit (e.g., spicy or 
high-fat meals such as curry or fish and chips or foods of a high-fiber content such as 
All-Bran) for 24 hours prior to admission until discharge from the study. 
For both study parts, subjects must not consume alcohol during the 24 hours prior to 
screening and the 24 hours prior to admission until discharge from the clinical unit. 
Subjects must not take part in any unaccustomed strenuous exercise from the 72 hours 
before the screening visit and then from 72 hours prior to admission until discharge from 
the clinical unit.  
Subjects must not donate blood or plasma (outside of this study), from clinical unit 
admission, throughout the study duration, and for at least 90 days following last dose of 
study medication. 
No food or fluids other than water will be allowed from 8 hours prior to each study visit 
until after study laboratory samples are obtained.   
In each study period, subjects will be provided with a light snack on the evening of 
Day -1 and no food will be allowed until 4 hours after dosing. 
Lunch will be provided at approximately 4 hours post-dose, an evening meal at 
approximately 10 hours post-dose and an evening snack at approximately 14 hours 
post-dose. 
On subsequent days, meals will be provided at appropriate times.  Meals will be similar 
among cohorts. 

 
GDC-9545—Genentech, Inc. 
47/Protocol GP42662 (QSC204283), Version 4 
Subjects will be allowed water up to 1 hour before the scheduled dosing time and will be 
provided with 240 mL of water at 1 hour post-dose.  Water will be allowed ad libitum 
after 1 hour post-dose.  Decaffeinated fluids will be allowed ad libitum from lunch time on 
the day of dosing. 
4.5 
STUDY ASSESSMENTS  
The schedule of activities to be performed during the study is provided in Appendix 1 for 
Part 1 and in Appendix 2 for Part 2.  All activities should be performed and documented 
for each subject.   
There are times where the protocol requires more than one procedure to be completed 
at the same time point.  In these instances, the following will apply to post-dose time 
points: 
• 
PK samples should take priority over other procedures scheduled at the same time 
point  
• 
ECGs should be taken prior to vital signs when both measurements are scheduled 
at the same time point  
• 
Other assessments, e.g., physical examinations etc., will be performed within the 
required time windows 
As guidance, the preferred order of assessments is: 
ECGs 
 
Vitals 
 
PK blood 
sampling 
(nominal 
time) 
 
Other assessments 
e.g., physical 
examinations 
 
All assessments will be timed and performed relative to the start of dosing. 
4.5.1 
Informed Consent Forms and Screening Log 
Written informed consent for participation in the study must be obtained before 
performing any study-related procedures (including screening evaluations).  Informed 
Consent Forms for enrolled subjects and for subjects who are not subsequently enrolled 
will be maintained at the study site. 
Subjects will be provided with a written explanation of the study at least the day before 
the screening visit.  A physician or nurse will explain to each subject the nature of the 
study, its purpose, expected duration and the benefits and risks involved in study 
participation.  Subjects will be informed that, for safety reasons, brief details of their 
involvement in the study may be revealed to other units and companies that carry out 
clinical studies in the local area.  Subjects will then be given the opportunity to ask 
questions and will be informed of their right to withdraw from the study without prejudice.  
After this explanation and before entering the study, the subject will voluntarily sign an 
ICF.  Until written consent has been obtained from the subject, no study specific 
procedure or investigation will be performed.  If an amendment is made to the participant 

 
GDC-9545—Genentech, Inc. 
48/Protocol GP42662 (QSC204283), Version 4 
information sheet, participants will be re consented to the most current version of the 
ICF(s) where appropriate. 
All screening evaluations must be completed and reviewed to confirm that subjects meet 
all eligibility criteria before enrollment.  The Investigator will maintain a screening log to 
record details of all subjects screened and to confirm eligibility or record reasons for 
screening failure, as applicable. 
Although only women of non-childbearing potential will be enrolled, and so the risk of 
pregnancy is very low, the risk associated with exposure to ionizing radiation to women 
who may be pregnant, will be discussed with female subjects.  They will be tested using 
a highly sensitive pregnancy screening kit prior to each study period.  Any subject found 
to be pregnant, or in whom pregnancy cannot reasonably be excluded, will be withdrawn 
from the study. 
If the start of the study is delayed for any reason so that the interval between screening 
and first dose exceeds 28 days, all or part of the screening procedures may be repeated 
at the discretion of the Investigator. 
This study permits the re-screening of a subject who has discontinued the study as a 
pre-treatment failure (i.e., subject has not been randomized/has not been treated); the 
reason for failure must be temporary and expected to resolve.  If re-screened, the 
subject must be re-consented. 
4.5.2 
Medical History, Baseline Conditions, Concomitant Medication, 
and Demographic Data 
Medical history, including clinically significant diseases, surgeries, cancer history 
(including prior cancer therapies and procedures), reproductive status, smoking history, 
and use of alcohol and drugs of abuse, will be recorded at baseline.  In addition, all 
medications (e.g., prescription drugs, over-the-counter drugs, HRT, vaccines, herbal or 
homeopathic remedies, nutritional supplements) used by the subject within 14 days prior 
to initiation of study treatment will be recorded.   
Demographic data will include age, sex, and self-reported race/ethnicity.  Height and 
weight will be recorded at screening. 
4.5.3 
Physical Examinations 
A complete physical examination, performed at screening, should include an evaluation 
of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatologic, 
musculoskeletal, respiratory, GI, genitourinary, and neurologic systems.  Any 
abnormality identified at baseline should be recorded on the Medical History. 
Limited, symptom-directed physical examinations should be performed at specified 
timepoints and as clinically indicated.  Changes from baseline abnormalities should be 

 
GDC-9545—Genentech, Inc. 
49/Protocol GP42662 (QSC204283), Version 4 
recorded in subject notes.  New or worsened clinically significant abnormalities should 
be recorded as adverse events on the Adverse Event eCRF. 
4.5.4 
Vital Signs  
Vital signs will include measurements of pulse rate, and systolic and diastolic blood 
pressure while the subject is in a supine position for 5 minutes, and oral temperature.   
The acceptable deviations from the nominal vital signs measurements time points are: 
• 
The pre-dose vital signs measurements will be taken ≤2 hours before dosing. 
• 
Post-dose vital signs measurements will be taken ± 15 minutes from the nominal 
post-dose time points. 
• 
Discharge vital signs measurements will be taken ± 1 hour from the nominal time 
point. 
Record abnormalities observed at baseline on the Medical History.  At subsequent visits, 
record new or worsened clinically significant abnormalities on the Adverse Event eCRF. 
4.5.5 
Laboratory and Other Biological  
When a subject withdraws from the study, samples collected prior to the date of 
withdrawal may still be analyzed, unless the subject specifically requests that the 
samples be destroyed or local laws require destruction of the samples.  However, if 
samples have been tested prior to withdrawal, results from those tests will remain as 
part of the overall research data. 
Data arising from sample analysis will be subject to the confidentiality standards 
described in Section 8.5. 
For sampling procedures, storage conditions, and shipment instructions, see the Clinical 
Sample Processing Manual. 
4.5.5.1 
Safety Laboratory Assessments 
Samples for the following laboratory tests will be sent to The Doctors Laboratory for 
analysis: 
• 
Hematology: white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin, 
hematocrit (packed cell volume), mean cell hemoglobin, mean cell hemoglobin 
concentration, mean cell volume, platelet count, and differential count (neutrophils, 
eosinophils, basophils, monocytes, lymphocytes) 
• 
Chemistry panel (serum):magnesium, sodium, potassium, chloride, glucose, fasting 
glucose, urea, creatinine, creatine kinase, total protein, albumin, phosphate 
(inorganic), calcium, total bilirubin, direct bilirubin (only if total is elevated), alkaline 
phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
gamma glutamyl transferase (GGT), and bicarbonate  

 
GDC-9545—Genentech, Inc. 
50/Protocol GP42662 (QSC204283), Version 4 
• 
Coagulation: international normalized ratio (INR), activated partial thromboplastin 
time (APTT), thrombin time and prothrombin time (PT) 
• 
Virology: HBsAg, HCV Antibody, HIV Antibody at screening 
• 
Estradiol and FSH (post-menopausal female subjects only) 
• 
Pregnancy test 
– 
All women will have a highly sensitive serum pregnancy test at screening and a 
highly sensitive urine pregnancy test at admission. 
• 
Urinalysis (pH, specific gravity, glucose, protein, ketones, blood, bilirubin, 
leukocytes, nitrites, urobilinogen) and urine drug screen samples will be analyzed by 
dipstick at the clinic.  Microbiology and/or microscopic urinalysis examination, at the 
discretion of the Investigator based on urinalysis results (sediment, RBCs, WBCs, 
casts, crystals, epithelial cells, bacteria) 
• 
The urine drug screen will test for the following: amphetamines, barbiturates, 
benzodiazepines, cocaine, marijuana/cannabis, methadone, 
methamphetamine/ecstasy, morphine/opiates, phencyclidine, and tricyclic 
anti-depressants.   
Scheduled blood samples for safety laboratory tests will be taken following an 8-hour 
fast.  The acceptable deviation from the nominal time points are as follows: 
• 
The pre-dose samples will be taken ≤2 hours before dosing 
• 
Post-dose samples will be taken ± 1 hour from the nominal sampling time 
CLcr will be calculated at screening by The Doctors Laboratory using the 
Cockcroft-Gault equation and body weight for eligibility purposes: 
CLcr (mL/min) = (140-age [years]) x (body weight [kg]) (× 1.04) 
 
serum creatinine (µmol/L) 
Alcohol breath tests and carbon monoxide breath tests will be performed at the clinic.  A 
positive alcohol breath test will exclude that subject from dosing during that admission.  
A carbon monoxide result of greater than 10 ppm will exclude the subject from the study. 
4.5.5.2 
Mass Balance, Pharmacokinetic and Metabolite Profiling and 
Identification Assessments 
Samples for the following laboratory tests will be sent to Covance for analysis: 
• 
Plasma samples for PK analysis of GDC-9545 
Samples for the following laboratory tests will be sent to Pharmaron for analysis: 
• 
Plasma, whole blood, urine and feces samples for analysis of TR (Part 1 only) 
• 
Other accidental sources of elimination for analysis of TR (Part 1 only) 

 
GDC-9545—Genentech, Inc. 
51/Protocol GP42662 (QSC204283), Version 4 
Samples for the following laboratory tests will be sent to the Sponsor for analysis: 
• 
Plasma, urine and feces samples for metabolite profiling and identification (Part 1 
only) 
Consent will be collected from the subjects for use of these samples for the purposes of 
the proposed study. 
In Part 1, a single urine sample will be taken at pre-dose (or the first void of the day) for 
the mass balance analysis.  Where a sample is not provided, this will not be considered 
a deviation.  All individual urine voids will be collected and shipped to Pharmaron for TR 
analysis, according to Quotient Sciences’ standard operating procedures, unless 
indicated otherwise by the Sponsor. 
In Part 1, the pre-dose fecal sample will be taken in the 24 hours period before dosing 
(between admission and pre-dose).  If a pre-dose fecal sample cannot be obtained, the 
subject will still be dosed.  Where a sample is not provided, this will not be considered a 
deviation. Samples will be shipped to Pharmaron for the analysis of TR. 
During Part 1 of the study, other accidental sources of elimination will be collected as 
voided (e.g., emesis).  Samples will be shipped to Pharmaron for the analysis of TR. 
Venous blood samples will be withdrawn via an indwelling cannula or by venipuncture 
(see Appendices 3 and 4 for detailed schedules for Parts 1 and 2, respectively).  The 
acceptable deviations from the nominal PK and metabolite profiling and identification 
blood sampling times are as follows: 
• 
The pre-dose samples will be taken ≤1 hour before dosing 
• 
0.25 to 0.5 hours post-dose samples will be taken within ± 2 minutes of the nominal 
post-dose sampling time 
• 
0.58 to 1 hour post-dose samples will be taken within ± 5 minutes of the nominal 
post-dose sampling time  
• 
1.5 to 8 hours post-dose samples will be taken within ± 15 minutes of the nominal 
post-dose sampling time 
• 
12 to 24 hours post-dose samples will be taken within ± 30 minutes of the nominal 
post-dose sampling time  
• 
48 to 480 hours post-dose samples will be taken within ± 4 hours of the nominal 
post-dose sampling time  
• 
648 to 984 hours post-dose samples will be taken within ± 1 day of the nominal 
post-dose sampling time  
For Treatment B, PK samples will be timed and performed relative to the start of the IV 
administration. 

 
GDC-9545—Genentech, Inc. 
52/Protocol GP42662 (QSC204283), Version 4 
The total blood volume for each subject will not exceed 550 mL in a 4-week period.  The 
first 0.5 mL of blood withdrawn via cannula will be discarded. 
Residual PK samples will be destroyed no later than 5 years after the final Clinical Study 
Report has been completed. 
4.5.6 
Electrocardiograms  
Single ECG recordings will be obtained at specified timepoints, as outlined in the 
schedule of activities (see Appendix 1 for Part 1 and Appendix 2 for Part 2).  The 
acceptable deviations from the nominal ECG measurement time points are: 
• 
The pre-dose ECG measurements will be taken ≤2 hours before dosing 
• 
Post-dose ECG measurements will be taken ± 15 minutes from the nominal 
post-dose time point.  
• 
Discharge ECG measurements will be taken ± 1 hour from the nominal time point.  
All ECG recordings must be performed using a standard high-quality, high-fidelity digital 
electrocardiograph machine equipped with computer-based interval measurements.  
Lead placement should be as consistent as possible.  ECG recordings must be 
performed after the subject has been resting in a supine position for at least 5 minutes.  
All ECGs are to be obtained prior to other procedures scheduled at that same time 
(e.g., vital sign measurements, blood draws) and should not be obtained within 3 hours 
after any meal, whenever feasible.  Circumstances that may induce changes in heart 
rate, including environmental distractions (e.g., television, radio, conversation), should 
be avoided during the pre-ECG resting period and during ECG recording. 
For safety monitoring purposes, the Investigator must review, sign, and date all ECG 
tracings.  Paper copies of ECG tracings will be kept as part of the subject's permanent 
study file at the site.  The following should be recorded in the appropriate eCRF: heart 
rate, RR interval, QRS interval, PR duration, uncorrected QT interval, and QTcF based 
on the machine readings of the individual ECG tracings.  Any morphologic waveform 
changes or other ECG abnormalities must be documented on the eCRF.  If considered 
appropriate by the Sponsor, ECGs may be analyzed retrospectively at a central 
laboratory. 
If at a particular post-dose timepoint the mean QTcF is  500 msec and/or 60 msec 
longer than the baseline value, another ECG must be recorded, ideally within the next 
5 minutes, and ECG monitoring should continue until QTcF has stabilized on two 
successive ECGs taken 30 minutes apart.  The Medical Monitor should be notified.  
Standard-of-care treatment may be instituted per the discretion of the Investigator.  If a 
PK sample is not scheduled for that timepoint, an unscheduled PK sample should be 
obtained.  A decision on study drug discontinuation should be made, as described in 
Section 4.6.1.  The Investigator should also evaluate the subject for potential concurrent 

 
GDC-9545—Genentech, Inc. 
53/Protocol GP42662 (QSC204283), Version 4 
risk factors (e.g., electrolyte abnormalities, co-medications known to prolong the QT 
interval, severe bradycardia). 
4.6 
TREATMENT, SUBJECT, STUDY, AND SITE 
DISCONTINUATION 
4.6.1 
Stopping Criteria 
The study will be halted, and the risk to other subjects evaluated if any of the following 
criteria are met:  
• 
A serious adverse reaction (i.e., a serious adverse event considered at least 
possibly related to the IMP administration) in one subject. 
• 
Severe non-serious adverse reactions (i.e., severe non-serious adverse event 
considered as, at least possibly related to the IMP administration) in two subjects in 
the same cohort, independent of within or not within the same system organ class. 
Relatedness will be determined by the Investigator.  
If the study is halted, a temporary halt will be submitted to the Medicines and Healthcare 
products Regulatory Agency (MHRA) and ethics committee (EC) in the form of a 
substantial amendment.  The study may be resumed or terminated; however, it will not 
be resumed until a further substantial amendment to resume the study is submitted and 
approved by MHRA and EC. 
The ARSAC Practitioner will also be informed of the temporary halt. 
In addition, subjects must permanently discontinue study treatment if they experience 
any of the following: 
• 
Any medical condition that the Investigator or Sponsor determines may jeopardize 
the subject's safety if he or she continues to receive study treatment 
• 
Investigator or Sponsor determination that treatment discontinuation is in the best 
interest of the subject 
• 
Pregnancy 
• 
Concurrent illness that would adversely affect subject safety or data integrity or 
requirement for prohibited medication 
• 
Experiencing a serious or severe adverse event including but not limited to: 
– 
corrected QT interval by Fridericia’s formula (QTcF) of >500 msec or increase in 
QTcF interval of >60 msec from baseline (confirmed following a repeat ECG) 
– 
ALT concentration >3 × the upper limit of the reference range (confirmed 
following a repeat ALT blood test) 
• 
Evidence of current SARS-CoV-2 infection   
 
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.  

 
GDC-9545—Genentech, Inc. 
54/Protocol GP42662 (QSC204283), Version 4 
For a subject who withdraws because of an IMP-related adverse event, every effort will 
be made to ensure the subject completes follow-up procedures.  Any subject withdrawn 
or discontinuing the study prematurely because of an IMP-related adverse event or 
termination of the study will be considered to have completed the study, and will not be 
replaced.  
Subjects who withdraw from Part 1 of the study will not be replaced. 
For Part 2 only, subjects who discontinue study treatment may be replaced at the 
discretion of the Sponsor and the Investigator to ensure a minimum of 8 evaluable 
subjects.  An evaluable subject for Part 2 of the study is defined as a subject who has 
received an IMP and has sufficient drug concentration measurements up to 168 hours 
after dosing for evaluation of defined PK parameters for each treatment, and have 
completed all planned safety assessments up to 168 hours after dosing for each 
treatment. 
4.6.2 
Subject Discontinuation from the Study 
Subjects have the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the Investigator has the right to withdraw a subject from the study at any 
time. 
Reasons for subject discontinuation from the study may include, but are not limited to, 
the following: 
• 
Subject withdrawal of consent 
• 
Study termination or site closure 
• 
Adverse event 
• 
Loss to follow-up 
• 
Subject non-compliance, defined as failure to comply with protocol requirements as 
determined by the Investigator or Sponsor 
 
Every effort should be made to obtain a reason for subject discontinuation from the 
study.  The primary reason for discontinuation from the study should be documented on 
the appropriate eCRF.  If a subject requests to be withdrawn from the study, this request 
must be documented in the source documents and signed by the Investigator.   
For a subject who withdraws because of an IMP-related adverse event, every effort will 
be made to ensure the subject completes follow-up procedures.  Any subject withdrawn 
or discontinuing the study prematurely because of an IMP-related adverse event or 
termination of the study will be considered to have completed the study, and will not be 
replaced.  
Subjects who withdraw from Part 1 of the study will not be replaced. 

 
GDC-9545—Genentech, Inc. 
55/Protocol GP42662 (QSC204283), Version 4 
For Part 2 only, subjects who discontinue study treatment may be replaced at the 
discretion of the Sponsor and the Investigator to ensure a minimum of 8 evaluable 
subjects.  An evaluable subject for Part 2 of the study is defined as a subject who has 
received an IMP and has sufficient drug concentration measurements up to 168 hours 
after dosing for evaluation of defined PK parameters for each treatment, and have 
completed all planned safety assessments up to 168 hours after dosing for each 
treatment. 
4.6.3 
Study Discontinuation 
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following: 
• 
The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to subjects 
• 
Subject enrollment is unsatisfactory 
The Sponsor will notify the Investigator if the Sponsor decides to discontinue the study. 
After the start of protocol activities but prior to the commencement of dosing, the study 
may be terminated by the Sponsor and Investigator without consultation with the MHRA, 
EC, ARSAC Practitioner or ARSAC.  The ARSAC Practitioner and ARSAC (if ARSAC 
research application has been submitted or approved) must be notified promptly, in 
writing, that the study will no longer be taking place.  Notification of early termination 
should also be provided to the EC and MHRA within 15 days, clearly explaining the 
reasons for the termination. 
If the study is abandoned prior to commencement of any protocol activities, the 
Investigator or Sponsor must notify the EC, MHRA, ARSAC Practitioner and ARSAC (if 
ARSAC research application has been submitted or approved) in writing outlining the 
reasons for abandonment of the trial. 
New information regarding the safety of the IMP that indicates a change in the 
risk/benefit profile for the compound, such that the risk/benefit is no longer acceptable 
for subjects participating in the study may also mean termination of the study prior to 
dosing.  
Once exposure to dosing has begun, the study will be completed as planned unless the 
following criteria are satisfied that require a temporary halt or early termination of the 
study.  
• 
The occurrence of serious or severe adverse event(s), if considered to be related to 
the IMP, on the dosing day. 
• 
Significant violation of Good Clinical Practice (GCP) that compromises the ability to 
achieve the primary study objectives or compromises subject safety. 

 
GDC-9545—Genentech, Inc. 
56/Protocol GP42662 (QSC204283), Version 4 
If any of the above occurs, the study will be terminated if careful review of the overall 
risk/benefit analysis demonstrates that the assumptions have changed and that the 
overall balance is no longer acceptable.  In these circumstances, termination can only 
take place with the agreement of the Investigator and Sponsor.  The MHRA, EC, ARSAC 
Practitioner and ARSAC will be informed of study termination. 
If it becomes necessary to consider termination of the study on the dosing day, dosing 
may be suspended pending discussion between the Investigator, Sponsor and ARSAC 
Practitioner).  Dosing will be stopped immediately on safety grounds. 
The study may be terminated or suspended at the request of the MHRA or EC.  
4.6.4 
Site Discontinuation 
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following: 
• 
Excessively slow recruitment 
• 
Poor protocol adherence 
• 
Inaccurate or incomplete data recording 
• 
Non-compliance with the International Council for Harmonisation (ICH) guideline for 
GCP 
• 
No study activity (i.e., all subjects have completed the study and all obligations have 
been fulfilled) 
 
5. 
ASSESSMENT OF SAFETY  
5.1 
SAFETY PLAN  
GDC-9545 is not approved, and clinical development is ongoing.  The safety plan for 
volunteers in this study is based on clinical experience with GDC-9545 in completed and 
ongoing studies.  The anticipated important safety risks for this study are outlined below.  
Please refer to the GDC-9545 IB for a complete summary of safety information. 
Several measures will be taken to ensure the safety of subjects participating in this 
study.  Eligibility criteria have been designed to exclude subjects at higher risk for 
toxicities.  Subjects will undergo safety monitoring during the study, including 
assessment of the nature, frequency, and severity of adverse events.   
5.1.1 
Risks Associated with GDC-9545  
As of the data cutoff of 31 Jan 2020, the safety of GDC-9545 has previously been 
evaluated in a comprehensive pre-clinical safety program and in clinical studies in more 
than 160 ER+ breast cancer patients.  Preclinical and clinical findings for GDC-9545 are 
summarized in Section 1.2. 

 
GDC-9545—Genentech, Inc. 
57/Protocol GP42662 (QSC204283), Version 4 
Overall, GDC-9545 was well tolerated at all dose levels in patients with early breast 
cancer; all reported adverse events have been Grade 1 or 2 severity, except a Grade 3 
serious adverse event of breast abscess in one patient at 10 mg dose level, which was 
considered unrelated to GDC-9545 by the Investigator.  With the exception of one event 
of fatigue (which was also considered related to progressive disease), no serious 
adverse drug reactions have been reported in the single agent studies; additionally, no 
identified risks have been confirmed for GDC-9545.  
On the basis of nonclinical toxicology findings for GDC-9545 and known toxicities 
associated with other drugs in the ER antagonist class, the potential risks of GDC-9545 
are hepatotoxicity, GI toxicities, venous thromboembolic events, bradycardia, renal 
dysfunction, changes in female reproductive organs and menopausal symptoms, 
male/female infertility, QT prolongation and embryofetal toxicity.  These potential risks 
will be managed as outlined in Section 1.3.2. 
GDC-9545 has been assessed to have a low potential for clinically relevant Cytochrome 
P450 mediated drug-drug interactions.  Nonetheless, potential drug-drug interactions 
with other medications will be avoided by restrictions on concomitant medication use. 
In pre-clinical toxicity studies, GDC-9545 was found to be not mutagenic in the bacterial 
mutagenesis assay, did not induce an increase in micronucleus formation in human 
lymphocytes in in vitro studies and was not phototoxic in an in vitro mammalian 
cell-based assay. 
Overall, no significant safety concerns have been identified about the use of 30 mg 
GDC-9545 in healthy volunteers. 
5.1.2 
Risks Associated with Radiation 
Subjects will be exposed to ionizing radiation of NMT 4.6 MBq (124 µCi) [14C].  The 
effective dose that each subject will receive from one administration of 4.6 MBq 
(124 µCi) [14C] will not exceed 0.7 mSv.  This is approximately 3.1 months of the 
average radiation exposure received in the UK each year (2.7 mSv; data obtained from 
Public Health England Ionising Radiation Exposure of the UK Population: 2010 Review) 
and is equivalent to slightly less than the radiation dose that would result from 2 x-rays of 
the abdomen.  An increase in the amount of radiation that is received above natural 
radiation carries a risk of later developing serious and possibly fatal conditions.  
However, the risk associated with the maximum possible dose of radiation in this study 
is very small indeed and is considered to be acceptable. 
5.1.3 
COVID-19 Related Risks and Risk Mitigation Measures 
The following risks and risk mitigating measures apply to the time in which the study is 
conducted during the COVID-19 pandemic. 

 
GDC-9545—Genentech, Inc. 
58/Protocol GP42662 (QSC204283), Version 4 
5.1.3.1 
IMP-Related Risk 
Against the background of the COVID-19 pandemic, the potential risk of a subject 
developing COVID-19 has been considered in terms of the risk-benefit evaluation.  The 
mode of action of the IMP – as ER antagonist – has been considered alongside 
available pre-clinical and clinical data (including class effects) and it is considered that a 
subject would not be at increased risk of either becoming infected with SARS-CoV-2 (the 
virus that causes COVID-19) or experiencing a more severe illness.  That is, the IMP 
has no known immunomodulatory effect that would confer an increased risk to healthy 
subjects enrolled in the study. 
5.1.3.2 
General COVID-19-Related Risk Mitigation Measures 
General risk mitigation against COVID-19 will be implemented in accordance with 
Quotient Sciences’ monitoring and prevention control measures. 
The risk mitigation measures, where applicable, will be amended based on emerging 
government guidance. 
5.1.4 
General Risks 
Collecting a blood sample from a vein may cause pain, swelling, bruising, light 
headedness, fainting, and very rarely, clot formation, nerve damage and/or infection at 
the site of the needle stick. 
During cannulation, more than one attempt may be needed to insert the cannula in a 
vein of a subject and it is possible that bruising and/or inflammation may be experienced 
at the site of cannulation.  
Electrocardiogram (ECG) stickers on the subjects' chests and limbs may cause some 
local irritation and may be uncomfortable to remove but subjects will be closely 
monitored to ensure any local irritation does not persist. 
5.2 
SAFETY PARAMETERS AND DEFINITIONS 
Safety assessments will consist of monitoring and recording adverse events, including 
serious adverse events and adverse events of special interest, performing 
protocol-specified safety laboratory assessments, measuring protocol-specified vital 
signs, and conducting other protocol-specified tests that are deemed critical to the safety 
evaluation of the study. 
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4. 

 
GDC-9545—Genentech, Inc. 
59/Protocol GP42662 (QSC204283), Version 4 
5.2.1 
Adverse Events 
According to the ICH guideline for GCP, an adverse event is any untoward medical 
occurrence in a clinical investigation subject administered a pharmaceutical product, 
regardless of causal attribution.  An adverse event can therefore be any of the following: 
• 
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product 
• 
Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition) (see Section 5.3.5.9 for more 
information) 
• 
Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline 
• 
Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug 
• 
Adverse events that are related to a protocol-mandated intervention, including those 
that occur prior to assignment of study treatment (e.g., screening invasive 
procedures such as biopsies) 
 
5.2.2 
Serious Adverse Events (Immediately Reportable to the 
Sponsor) 
A serious adverse event is any adverse event that meets any of the following criteria: 
• 
Is fatal (i.e., the adverse event actually causes or leads to death) 
• 
Is life threatening (i.e., the adverse event, in the view of the Investigator, places the 
subject at immediate risk of death) 
This does not include any adverse event that, had it occurred in a more severe 
form or was allowed to continue, might have caused death. 
• 
Requires or prolongs subject hospitalization (see Section 5.3.5.10) 
• 
Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the subject's ability to conduct normal life 
functions) 
• 
Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug 
• 
Is a significant medical event in the Investigator's judgment (e.g., may jeopardize 
the subject or may require medical/surgical intervention to prevent one of the 
outcomes listed above) 
 
The terms "severe" and "serious" are not synonymous.  Severity refers to the intensity of 
an adverse event (e.g., rated as mild, moderate, or severe, or according to National 
Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE]; see 

 
GDC-9545—Genentech, Inc. 
60/Protocol GP42662 (QSC204283), Version 4 
Section 5.3.3); the event itself may be of relatively minor medical significance (such as 
severe headache without any further findings). 
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF. 
Serious adverse events are required to be reported by the Investigator to the Sponsor 
immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 
for reporting instructions). 
5.2.3 
Adverse Events of Special Interest (Immediately Reportable to 
the Sponsor) 
Adverse events of special interest are required to be reported by the Investigator to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 for reporting instructions).  Adverse events of special interest for this study 
are as follows: 
• 
Cases of potential drug-induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's 
Law (see Section 5.3.5.7) 
• 
Cases of potential drug-induced kidney injury 
• 
Grade ≥3 nausea/vomiting/diarrhea 
• 
Grade ≥2 thromboembolic events (pulmonary embolism, deep vein thrombosis, and 
embolism) 
• 
Grade ≥3 renal failure (including acute kidney injury or other similar medical 
concepts) 
• 
Grade ≥3 hepatitis or elevation in ALT or AST 
• 
Grade ≥2 vaginal or uterine hemorrhage 
• 
Grade ≥2 bradycardia 
• 
Any grade of endometrial cancer. 
• 
Suspected transmission of an infectious agent by the study drug, as defined below 
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a subject exposed to a medicinal product.  This term applies only 
when a contamination of the study drug is suspected. 
  

 
GDC-9545—Genentech, Inc. 
61/Protocol GP42662 (QSC204283), Version 4 
5.3 
METHODS AND TIMING FOR CAPTURING AND ASSESSING 
SAFETY PARAMETERS 
The Investigator is responsible for ensuring that all adverse events (see Section 5.2.1 for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Sections 5.4−5.6. 
For each adverse event recorded on the Adverse Event eCRF, the Investigator will make 
an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see 
Section 5.3.3), and causality (see Section 5.3.4).   
5.3.1 
Adverse Event Reporting Period 
Investigators will seek information on adverse events at each subject contact.  All 
adverse events, whether reported by the subject or noted by study personnel, will be 
recorded in the subject's medical record and on the Adverse Event eCRF. 
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol-mandated intervention (e.g., invasive 
procedures such as biopsies, discontinuation of medications) should be reported 
(see Section 5.4.2 for instructions for reporting serious adverse events). 
After initiation of study drug, all adverse events will be reported until 28 days after the 
final dose of study drug. 
Instructions for reporting adverse events that occur after the adverse event reporting 
period are provided in Section 5.6. 
5.3.2 
Eliciting Adverse Event Information 
A consistent methodology of non-directive questioning should be adopted for eliciting 
adverse event information at all subject evaluation timepoints.  Examples of 
non-directive questions include the following: 
"How have you felt since your last clinic visit?" 
"Have you had any new or changed health problems since you were last here?" 
 
5.3.3 
Assessment of Severity of Adverse Events  
The adverse event severity grading scale for the NCI CTCAE (v5.0) will be used for 
assessing adverse event severity.  Table 5 will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE. 

 
GDC-9545—Genentech, Inc. 
62/Protocol GP42662 (QSC204283), Version 4 
Table 5 
Adverse Event Severity Grading Scale for Events Not Specifically 
Listed in NCI CTCAE 
Grade 
Severity 
1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
or intervention not indicated 
2 
Moderate; minimal, local, or non-invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily living a 
3 
Severe or medically significant, but not immediately life threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; or 
limiting self-care activities of daily living b, c 
4 
Life-threatening consequences or urgent intervention indicated d 
5 
Death related to adverse event d 
NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events. 
Note:  Based on the most recent version of NCI CTCAE (v5.0), which can be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic applications/ctc.htm 
a Instrumental activities of daily living refer to preparing meals, shopping for groceries or 
clothes, using the telephone, managing money, etc. 
b Examples of self-care activities of daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by subjects who are 
not bedridden. 
c If an event is assessed as a "significant medical event," it must be reported as a serious 
adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious 
adverse event in Section 5.2.2. 
d Grade 4 and 5 events must be reported as serious adverse events (see Section  5.4.2 for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2. 
 
5.3.4 
Assessment of Causality of Adverse Events 
Investigators should use their knowledge of the subject, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an 
adverse event is considered to be related to the study drug, indicating "yes" or "no" 
accordingly.  The following guidance should be taken into consideration (see also 
Table 6: 
• 
Temporal relationship of event onset to the initiation of study drug 
• 
Course of the event, with special consideration of the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable) 
• 
Known association of the event with the study drug or with similar treatments 
• 
Known association of the event with the disease under study 
• 
Presence of risk factors in the subject or use of concomitant medications known to 
increase the occurrence of the event 
• 
Presence of non-treatment-related factors that are known to be associated with the 
occurrence of the event 
 

 
GDC-9545—Genentech, Inc. 
63/Protocol GP42662 (QSC204283), Version 4 
Table 6 
Causal Attribution Guidance 
Is the adverse event suspected to be caused by the study drug on the basis of facts, evidence, 
science-based rationales, and clinical judgment? 
YES 
There is a plausible temporal relationship between the onset of the adverse event and 
administration of the study drug, and the adverse event cannot be readily explained by 
the subject's clinical state, intercurrent illness, or concomitant therapies; and/or the 
adverse event follows a known pattern of response to the study drug; and/or the 
adverse event abates or resolves upon discontinuation of the study drug or dose 
reduction and, if applicable, reappears upon re-challenge. 
NO 
An adverse event will be considered related, unless it fulfills the criteria specified below.   
Evidence exists that the adverse event has an etiology other than the study drug 
(e.g., preexisting medical condition, underlying disease, intercurrent illness, 
or concomitant medication); and/or the adverse event has no plausible temporal 
relationship to administration of the study drug (e.g., cancer diagnosed 2 days after 
first dose of study drug). 
For subjects receiving combination therapy, causality will be assessed individually for 
each protocol-mandated therapy. 
5.3.5 
Procedures for Recording Adverse Events 
Investigators should use correct medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations. 
Only one adverse event term should be recorded in the event field on the Adverse Event 
eCRF. 
5.3.5.1 
Infusion-Related Reactions 
Adverse events that occur during or within 24 hours after study drug administration and 
are judged to be related to study drug infusion should be captured as a diagnosis (e.g., 
"infusion-related reaction" or "anaphylactic reaction”) on the Adverse Event eCRF.  If 
possible, avoid ambiguous terms such as "systemic reaction."  Associated signs and 
symptoms should be recorded on the dedicated Infusion-Related Reaction eCRF.  If a 
subject experiences both a local and systemic reaction to the same dose of study drug, 
each reaction should be recorded separately on the Adverse Event eCRF, with signs 
and symptoms also recorded separately on the dedicated Infusion-Related Reaction 
eCRF. 
5.3.5.2 
Diagnosis versus Signs and Symptoms 
A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than 
individual signs and symptoms (e.g., record only liver failure or hepatitis rather than 
jaundice, asterixis, and elevated transaminases).  However, if a constellation of signs 
and/or symptoms cannot be medically characterized as a single diagnosis or syndrome 
at the time of reporting, each individual event should be recorded on the Adverse Event 
eCRF.  If a diagnosis is subsequently established, all previously reported adverse events 
based on signs and symptoms should be nullified and replaced by one adverse event 

 
GDC-9545—Genentech, Inc. 
64/Protocol GP42662 (QSC204283), Version 4 
report based on the single diagnosis, with a starting date that corresponds to the starting 
date of the first symptom of the eventual diagnosis. 
5.3.5.3 
Adverse Events That Are Secondary to Other Events 
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by their primary cause, with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example: 
• 
If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF. 
• 
If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF. 
• 
If a severe GI hemorrhage leads to renal failure, both events should be reported 
separately on the eCRF. 
• 
If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF. 
• 
If neutropenia is accompanied by an infection, both events should be reported 
separately on the eCRF. 
 
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated. 
5.3.5.4 
Persistent or Recurrent Adverse Events 
A persistent adverse event is one that extends continuously, without resolution, between 
subject evaluation timepoints.  Such events should only be recorded once on the 
Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persistent adverse event becomes 
more severe, the most extreme severity should also be recorded on the Adverse Event 
eCRF.  If the event becomes serious, it should be reported to the Sponsor immediately 
(i.e., no more than 24 hours after learning that the event became serious; see 
Section 5.4.2 for reporting instructions).  The Adverse Event eCRF should be updated 
by changing the event from "non-serious" to "serious," providing the date that the event 
became serious, and completing all data fields related to serious adverse events. 
A recurrent adverse event is one that resolves between subject evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF. 
5.3.5.5 
Abnormal Laboratory Values 
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria: 
• 
Is accompanied by clinical symptoms 

 
GDC-9545—Genentech, Inc. 
65/Protocol GP42662 (QSC204283), Version 4 
• 
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation) 
• 
Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy 
• 
Is clinically significant in the Investigator's judgment 
 
It is the Investigator's responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event. 
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5  upper limit of normal [ULN] associated with 
cholestasis), only the diagnosis (i.e., cholestasis) should be recorded on the Adverse 
Event eCRF. 
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating whether the test result is above or below the normal range 
(e.g., "elevated potassium," as opposed to "abnormal potassium").  If the laboratory 
abnormality can be characterized by a precise clinical term per standard definitions, the 
clinical term should be recorded as the adverse event.  For example, an elevated serum 
potassium level of 7.0 mEq/L should be recorded as "hyperkalemia." 
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.4 for 
details on recording persistent adverse events). 
5.3.5.6 
Abnormal Vital Sign Values 
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it meets any of the following criteria: 
• 
Is accompanied by clinical symptoms 
• 
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation) 
• 
Results in a medical intervention or a change in concomitant therapy 
• 
Is clinically significant in the Investigator's judgment  
 
It is the Investigator's responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event. 
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on 
the Adverse Event eCRF. 

 
GDC-9545—Genentech, Inc. 
66/Protocol GP42662 (QSC204283), Version 4 
Observations of the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.4 for 
details on recording persistent adverse events). 
5.3.5.7 
Abnormal Liver Function Tests 
The finding of an elevated ALT or AST ( 3  ULN) in combination with either an elevated 
total bilirubin ( 2  ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as 
defined by Hy's Law).  Therefore, Investigators must report as an adverse event the 
occurrence of either of the following: 
• 
Treatment-emergent ALT or AST  3  ULN in combination with total bilirubin 
 2  ULN 
• 
Treatment-emergent ALT or AST  3  ULN in combination with clinical jaundice 
 
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.2) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or an adverse event of special interest (see 
Section 5.4.2). 
5.3.5.8 
Deaths 
All deaths that occur during the protocol-specified adverse event reporting period (see 
Section 5.3.1), regardless of relationship to study drug, must be recorded on the 
Adverse Event eCRF and immediately reported to the Sponsor (see Section 5.4.2).   
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, "unexplained death" should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), "unexplained death" should 
be replaced by the established cause of death.  The term "sudden death" should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death"). 
Deaths that occur after the adverse event reporting period should be reported as 
described in Section 5.6. 
5.3.5.9 
Preexisting Medical Conditions 
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the Medical History. 
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  When 
recording such events on the Adverse Event eCRF, it is important to convey the concept 

 
GDC-9545—Genentech, Inc. 
67/Protocol GP42662 (QSC204283), Version 4 
that the preexisting condition has changed by including applicable descriptors 
(e.g., "more frequent headaches"). 
5.3.5.10 
Hospitalization or Prolonged Hospitalization 
Any adverse event that results in hospitalization (i.e., inpatient admission to a hospital) 
or prolonged hospitalization should be documented and reported as a serious adverse 
event (per the definition of serious adverse event in Section 5.2.2), except as outlined 
below.   
An event that leads to hospitalization under the following circumstances should not be 
reported as an adverse event or a serious adverse event: 
• 
Hospitalization for a preexisting condition, provided that all of the following criteria 
are met: 
The hospitalization was planned prior to the study or was scheduled during the 
study when elective surgery became necessary because of the expected 
normal progression of the disease 
The subject has not experienced an adverse event 
 
An event that leads to hospitalization under the following circumstances is not 
considered to be a serious adverse event, but should be reported as an adverse event 
instead: 
• 
Hospitalization that was necessary because of subject requirement for outpatient 
care outside of normal outpatient clinic operating hours 
 
5.3.5.11 
Cases of Accidental Overdose or Medication Error  
Accidental overdose and medication error (hereafter collectively referred to as "special 
situations"), are defined as follows: 
• 
Accidental overdose:  accidental administration of a drug in a quantity that is higher 
than the assigned dose 
• 
Medication error:  accidental deviation in the administration of a drug  
In some cases, a medication error may be intercepted prior to administration of 
the drug. 
 
Special situations are not in themselves adverse events, but may result in adverse 
events.  Each adverse event associated with a special situation should be recorded 
separately on the Adverse Event eCRF.  If the associated adverse event fulfills 
seriousness criteria, the event should be reported to the Sponsor immediately 
(i.e., no more than 24 hours after learning of the event; see Section 5.4.2).  For 
GDC-9545 and [14C]-GDC-9545, adverse events associated with special situations 
should be recorded as described below for each situation: 
• 
Accidental overdose:  Enter the adverse event term.  Check the "Accidental 
overdose" and "Medication error" boxes. 

 
GDC-9545—Genentech, Inc. 
68/Protocol GP42662 (QSC204283), Version 4 
• 
Medication error that does not qualify as an overdose:  Enter the adverse event 
term.  Check the "Medication error" box. 
• 
Medication error that qualifies as an overdose:  Enter the adverse event term.  
Check the "Accidental overdose" and "Medication error" boxes. 
 
In addition, all special situations associated with GDC-9545 or [14C]-GDC-9545, 
regardless of whether they result in an adverse event, should be recorded on the 
Adverse Event eCRF as described below: 
• 
Accidental overdose:  Enter the drug name and "accidental overdose" as the event 
term.  Check the "Accidental overdose" and "Medication error" boxes. 
• 
Medication error that does not qualify as an overdose:  Enter the name of the drug 
administered and a description of the error (e.g., wrong dose administered, wrong 
dosing schedule, incorrect route of administration, wrong drug, expired drug 
administered) as the event term.  Check the "Medication error" box. 
• 
Medication error that qualifies as an overdose:  Enter the drug name and "accidental 
overdose" as the event term.  Check the "Accidental overdose" and "Medication 
error" boxes.  Enter a description of the error in the additional case details. 
• 
Intercepted medication error:  Enter the drug name and "intercepted medication 
error" as the event term.  Check the "Medication error" box.  Enter a description of 
the error in the additional case details. 
 
As an example, an accidental overdose that resulted in a headache would require two 
entries on the Adverse Event eCRF, one entry to report the accidental overdose and one 
entry to report the headache.  The "Accidental overdose" and "Medication error" boxes 
would need to be checked for both entries. 
5.4 
IMMEDIATE REPORTING REQUIREMENTS FROM 
INVESTIGATOR TO SPONSOR 
Certain events require immediate reporting to allow the Sponsor to take appropriate 
measures to address potential new risks in a clinical trial.  The Investigator must report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than 24 hours after the Investigator learns of the event.  The following is a 
list of events that the Investigator must report to the Sponsor within 24 hours after 
learning of the event, regardless of relationship to study drug: 
• 
Serious adverse events (defined in Section 5.2.2; see Section 5.4.2 for details on 
reporting requirements) 
• 
Adverse events of special interest (defined in Section 5.2.3; see Section 5.4.2 for 
details on reporting requirements) 
• 
Pregnancies (see Section 5.4.3 for details on reporting requirements) 
 
For serious adverse events and adverse events of special interest, the Investigator must 
report new significant follow-up information to the Sponsor immediately (i.e., no more 

 
GDC-9545—Genentech, Inc. 
69/Protocol GP42662 (QSC204283), Version 4 
than 24 hours after becoming aware of the information).  New significant information 
includes the following: 
• 
New signs or symptoms or a change in the diagnosis 
• 
Significant new diagnostic test results 
• 
Change in causality based on new information 
• 
Change in the event's outcome, including recovery 
• 
Additional narrative information on the clinical course of the event 
 
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and EC. 
5.4.1 
Emergency Medical Contacts 
Medical Monitor Contact Information 
Genentech Medical Monitor contact information: 
Medical Monitors: 
MD, MPH (Primary) 
Telephone Nos.: 
(Mobile – USA) 
 
(Office – USA) 
ARSAC Practitioner Contact Information 
CRO ARSAC Practitioner contact information: 
ARSAC Practitioner: 
MB BChir, MRCGP, MFPM 
Telephone No.: 
(Mobile – UK) 
Email: 
  
5.4.2 
Reporting Requirements for Serious Adverse Events, Adverse 
Events of Special Interest 
5.4.2.1 
Events That Occur prior to Study Drug Initiation 
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol-mandated intervention should be reported.  
The paper Clinical Trial Serious Adverse Event/Adverse Event of Special Interest 
Reporting Form provided to Investigators should be completed and submitted to the 
Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the 
event), either by faxing or by scanning and emailing the form using the fax number or 
email address provided to Investigators: 
– 
Fax: 
or 
 or
or
– 
Email: welwyn.pds-pc@roche.com 

 
GDC-9545—Genentech, Inc. 
70/Protocol GP42662 (QSC204283), Version 4 
5.4.2.2 
Events That Occur after Study Drug Initiation 
After initiation of study drug, serious adverse events and adverse events of special 
interest will be reported until 28 days after the final dose of study drug.  Investigators 
should record all case details that can be gathered immediately (i.e., within 24 hours 
after learning of the event) on the Adverse Event eCRF and submit the report via the 
electronic data capture (EDC) system.  A report will be generated and sent to Safety 
Risk Management by the EDC system. 
In the event that the EDC system is unavailable, the paper Clinical Trial Serious Adverse 
Event/Adverse Event of Special Interest Reporting Form provided to Investigators should 
be completed and submitted to the Sponsor or its designee immediately (i.e., no more 
than 24 hours after learning of the event), either by faxing or by scanning and emailing 
the form using the fax number or email address provided to Investigators.  Once the 
EDC system is available, all information will need to be entered and submitted via the 
EDC system.   
Instructions for reporting serious adverse events that occur  28 days after the final dose 
of study treatment are provided in Section 5.6. 
5.4.3 
Reporting Requirements for Pregnancies 
5.4.3.1 
Pregnancies in Female Subjects 
Subjects will be instructed to immediately inform the Investigator if they become 
pregnant during the study or within 30 days after the final dose of study drug.  A paper 
Clinical Trial Pregnancy Reporting Form should be completed and submitted to the 
Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the 
pregnancy), either by faxing or by scanning and emailing the form using the fax number 
or email address provided to Investigators.  Pregnancy should not be recorded on the 
Adverse Event eCRF.  The Investigator should discontinue study drug and counsel the 
subject, discussing the risks of the pregnancy and the possible effects on the fetus.  
Monitoring of the subject should continue until conclusion of the pregnancy.  Any serious 
adverse events associated with the pregnancy (e.g., an event in the fetus, an event in 
the mother during or after the pregnancy, or a congenital anomaly/birth defect in the 
child) should be reported on the Adverse Event eCRF.  In addition, the Investigator will 
submit a Clinical Trial Pregnancy Reporting Form when updated information on the 
course and outcome of the pregnancy becomes available.   
5.4.3.2 
Abortions 
A spontaneous abortion should be classified as a serious adverse event (as the Sponsor 
considers abortions to be medically significant), recorded on the Adverse Event eCRF, 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event; see Section 5.4.2). 
If a therapeutic or elective abortion was performed because of an underlying maternal or 
embryofetal toxicity, the toxicity should be classified as a serious adverse event, 

 
GDC-9545—Genentech, Inc. 
71/Protocol GP42662 (QSC204283), Version 4 
recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2).  A therapeutic or 
elective abortion performed for reasons other than an underlying maternal or 
embryofetal toxicity is not considered an adverse event. 
All abortions should be reported as pregnancy outcomes on the paper Clinical Trial 
Pregnancy Reporting Form.  
5.4.3.3 
Congenital Anomalies/Birth Defects 
Any congenital anomaly/birth defect in a child born to a female subject exposed to study 
drug should be classified as a serious adverse event, recorded on the Adverse Event 
eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after 
learning of the event; see Section 5.4.2). 
5.5 
FOLLOW-UP OF SUBJECTS AFTER ADVERSE EVENTS 
5.5.1 
Investigator Follow-Up 
The Investigator should follow each adverse event until the event has resolved to 
baseline grade or better, the event is assessed as stable by the Investigator, the subject 
is lost to follow-up, or the subject withdraws consent.  Every effort should be made to 
follow all serious adverse events considered to be related to study drug or trial-related 
procedures until a final outcome can be reported. 
During the study period, resolution of adverse events (with dates) should be documented 
on the Adverse Event eCRF and in the subject's medical record to facilitate source data 
verification.  
All pregnancies reported during the study should be followed until pregnancy outcome. 
5.5.2 
Sponsor Follow-Up 
For serious adverse events, adverse events of special interest, and pregnancies, the 
Sponsor or a designee may follow up by telephone, fax, email, and/or a monitoring visit 
to obtain additional case details and outcome information (e.g., from hospital discharge 
summaries, consultant reports, autopsy reports) in order to perform an independent 
medical assessment of the reported case. 
5.6 
ADVERSE EVENTS THAT OCCUR AFTER THE ADVERSE 
EVENT REPORTING PERIOD 
The Sponsor should be notified if the Investigator becomes aware of any serious 
adverse event that occurs after the end of the adverse event reporting period (defined as 
28 days after the final dose of study drug), if the event is believed to be related to prior 
study drug treatment.  These events should be reported through use of the Adverse 
Event eCRF.  However, if the EDC system is not available, the Investigator should report 
these events directly to the Sponsor or its designee, either by faxing or by scanning and 
emailing the paper Clinical Trial Serious Adverse Event/Adverse Event of Special 

 
GDC-9545—Genentech, Inc. 
72/Protocol GP42662 (QSC204283), Version 4 
Interest Reporting Form using the fax number or email address provided to 
Investigators. 
5.7 
EXPEDITED REPORTING TO HEALTH AUTHORITIES, 
INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, 
AND ETHICS COMMITTEES 
The Sponsor will promptly evaluate all serious adverse events and adverse events of 
special interest against cumulative product experience to identify and expeditiously 
communicate possible new safety findings to Investigators, ECs, and applicable health 
authorities based on applicable legislation. 
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events through use of the reference safety 
information in the following reference document: 
• 
GDC-9545 IB 
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document. 
Reporting requirements will also be based on the Investigator's assessment of causality 
and seriousness, with allowance for upgrading by the Sponsor as needed. 
It is the responsibility of the Sponsor to determine whether an event requires expedited 
reporting and to notify the Investigator of their decision as soon as possible. 
Where expedited reporting is required, the following procedures should be followed. 
Fatal or life-threatening SUSARs 
Suspected unexpected serious adverse reactions (SUSARs) are adverse events that are 
believed to be related to an IMP and are both unexpected (i.e., the nature or severity is 
not expected from the information provided in the IB) and serious. SUSARs are subject 
to expedited reporting to the MHRA, EMA, and EC. 
It is the responsibility of the Sponsor to report fatal or life-threatening SUSARs to the 
MHRA as soon as possible, but no later than 7 calendar days after they first became 
aware of the reaction.  Any additional relevant information should be sent within 8 days 
of the report.   
The Sponsor is required to notify the EC of any SUSAR as soon as possible, but no later 
than 7 calendar days after they first became aware of the reaction.  Any additional 
relevant information should be sent within 8 days of the report.  The task of reporting 
fatal or life-threatening SUSARs may be delegated to the Investigator. 

 
GDC-9545—Genentech, Inc. 
73/Protocol GP42662 (QSC204283), Version 4 
The ARSAC Practitioner will be notified of any fatal or life-threatening SUSAR that is 
considered related to the exposure to radioactivity. 
Other SUSARs 
It is the responsibility of the Sponsor to report other SUSARs to the MHRA as soon as 
possible, but no later than 15 calendar days after they first became aware of the 
reaction.   
The Sponsor is required to notify the EC of other SUSARs as soon as possible, but no 
later than 15 calendar days after they first became aware of the reaction.  The task of 
reporting other SUSARs may be delegated to the Investigator. 
The ARSAC Practitioner will be notified of any SUSAR that is considered related to the 
exposure to radioactivity. 
 
6. 
STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN 
The primary objectives of Part 1 of this study is to characterize the absorption, 
metabolism, excretion, PK of GDC-9545.  No formal statistical analysis will be performed 
for Part 1 of this study.  
The primary objectives of Part 2 of this study are to evaluate the absolute and relative 
bioavailability of GDC-9545.  A mixed-effect analysis of variance model for the 
two-period crossover design will be used for formulation comparison.  A separate mixed-
effect analysis of variance model will be used for the absolute bioavailability comparison. 
Descriptive statistics (e.g., mean, median, standard deviation, minimum, maximum and 
number of subjects with an observation [n]) will be calculated for PK, mass balance and 
safety data in both Parts 1 and 2 of the study.  Additional statistics will be provided for 
PK-related data, including coefficient of variation (CV%), geometric mean and geometric 
CV%. 
All safety, mass balance recovery, and PK data will be listed. 
A study specific Statistical Analysis Plan (SAP) will be produced which will detail the 
statistical and reporting requirement for the study in more detail. The SAP will be 
finalized prior to database lock.  
6.1 
DETERMINATION OF SAMPLE SIZE 
For Part 1, it is planned to enroll 6 subjects to ensure data in a minimum of 4 evaluable 
subjects.  For Part 2, it is planned to enroll 10 subjects to ensure data in a minimum of 
8 evaluable subjects.  No replacement subjects are to be used in Part 1 of this study.  
Up to 4 replacement subjects are permitted in Part 2 of this study to ensure there are 
8 evaluable subjects. 

 
GDC-9545—Genentech, Inc. 
74/Protocol GP42662 (QSC204283), Version 4 
The study is exploratory and no formal sample size calculation has been made.  Based 
on experience from previous studies of a similar design, a sample size of 6 subjects for 
Part 1 and 10 subjects for Part 2 is considered appropriate to meet the objectives of the 
study. 
6.2 
SUMMARIES OF CONDUCT OF STUDY 
The number of subjects who enroll, are randomized (Part 2 only), are dosed, 
discontinue, or complete the study will be summarized.  Reasons for premature study 
discontinuation will be listed and summarized.  Enrollment and major protocol deviations 
will be listed and evaluated for their potential effects on the interpretation of study 
results. 
6.3 
SUMMARIES OF DEMOGRAPHIC AND BASELINE 
CHARACTERISTICS 
Demographic and baseline characteristics (including age, sex, race/ethnicity, height, 
weight, and BMI) will be summarized using means, standard deviations, medians, and 
ranges for continuous variables and proportions for categorical variables, as appropriate.  
For Part 1, summaries will be presented overall. For Part 2, summaries will be presented 
by treatment sequence; if all subjects receive all treatments, summaries will be 
presented overall only, unless a sequence effect is observed in the formal statistical 
analyses described below. Additionally, all data will be listed. 
Demographic and baseline characteristics will be recorded at screening. 
6.4 
MASS BALANCE ANALYSES (PART 1 ONLY) 
Urine and fecal samples will be collected for the analysis of TR in Part 1.  The following 
mass balance parameters will be calculated by Quotient Sciences from urine and feces 
separately and total (urine and feces combined):  
• 
Aeu: amount of TR excreted in urine 
• 
CumAeu: cumulative amount of TR excreted in urine 
• 
Feu: amount of TR excreted in urine expressed as a percentage of the radioactive 
dose administered 
• 
CumFeu: cumulative amount of TR excreted in urine expressed as a percentage of 
the radioactive dose administered 
• 
Aef: amount of TR eliminated in feces 
• 
CumAef: cumulative amount of TR eliminated in feces 
• 
Fef: amount of TR eliminated in feces expressed as a percentage of the radioactive 
dose administered 
• 
CumFef: cumulative amount of TR eliminated in feces expressed as a percentage of 
the radioactive dose administered 
• 
Aetotal: amount of TR excreted in urine and feces combined 

 
GDC-9545—Genentech, Inc. 
75/Protocol GP42662 (QSC204283), Version 4 
• 
CumAetotal: cumulative amount of TR excreted in urine and feces combined 
• 
Fetotal: amount of TR excreted in urine and feces combined expressed as a 
percentage of the radioactive dose administered 
• 
CumFetotal: cumulative amount of TR excreted in urine and feces combined 
expressed as a percentage of the radioactive dose administered 
 
6.5 
PHARMACOKINETIC ANALYSES 
The PK analysis population will consist of subjects with sufficient data to enable 
estimation of key parameters (e.g., AUC, time to maximum concentration [tmax], 
maximum concentration [Cmax], half-life [t1/2) with subjects grouped according to 
treatment received.  
Plasma GDC-9545, plasma TR and whole blood TR concentration data will be listed and 
summarized by treatment using descriptive statistics.  Individual and mean concentration 
versus time profiles will be plotted. 
The PK of GDC-9545 in plasma and TR in whole blood and plasma will be summarized 
by estimating the following parameters (as appropriate for data collected): 
• 
Cmax: maximum observed concentration 
• 
tmax: time of maximum observed concentration 
• 
AUC0-t: area under the curve from time 0 to the time of last measurable 
concentration 
• 
AUC0-inf: area under the curve from time 0 extrapolated to infinity 
• 
λZ: first order rate constant associated with the terminal (log-linear) portion of the 
curve 
• 
t1/2: terminal elimination half-life 
• 
CL: total body clearance calculated after a single IV administration (for GDC-9545 
only; Part 2 IV dose only) 
• 
CL/F: total body clearance calculated after a single extravascular administration 
where F (fraction of dose bioavailable) is unknown (for GDC-9545 only; oral doses 
only) 
• 
Vz: volume of distribution based on the terminal phase calculated using AUC0-inf after 
a single IV administration (for GDC-9545 only; Part 2 IV dose only) 
• 
Vz/F: apparent volume of distribution (for GDC-9545 only; oral doses only) 
• 
Ratio between whole blood and plasma concentrations for TR (Part 1 only) 
• 
Ratio between whole blood and plasma AUC0-inf values for TR (Part 1 only) 
• 
F: Absolute bioavailability calculated using AUC0-inf (for GDC-9545 only; oral doses 
in Part 2 only) 

 
GDC-9545—Genentech, Inc. 
76/Protocol GP42662 (QSC204283), Version 4 
• 
Frel Cmax: Relative bioavailability based on Cmax (for GDC-9545 only; GDC-9545/F18 
capsule, 30 mg in Part 2 only) 
• 
Frel AUC0-t: Relative bioavailability based on AUC0-t (for GDC-9545 only; 
GDC-9545/F18 capsule, 30 mg in Part 2 only) 
• 
Frel AUC0-inf: Relative bioavailability based on AUC0-inf (for GDC-9545 only; 
GDC-9545/F18 capsule, 30 mg in Part 2 only) 
The absolute bioavailability of GDC-9545/F12 capsule and GDC-9545/F18 capsule will 
be calculated using the AUC0-inf values obtained after oral and IV administration of 
GDC-9545. The mixed-effect analysis of variance model will be used for absolute 
bioavailability determination. The model will include formulation and period as fixed 
effects and a random subject effect. 
To evaluate the relative bioavailability of GDC-9545 as GDC-9545/F18 capsule 
compared to GDC-9545/F12 capsule, the PK parameters Cmax and AUC0-inf for 
GDC-9545 will be analyzed.  The mixed-effect analysis of variance model for the 
two-period crossover design will be used for formulation comparison.  The model will 
include formulation and period as fixed effects and random subject effect (i.e., assuming 
a compound symmetry covariance structure).  
Log-transformed Cmax, AUC0-t, and AUC0-inf values will be evaluated to estimate ratios of 
geometric mean values and the corresponding 90% confidence intervals (CIs) (test: 
GDC-9545/F18 capsule, reference: GDC-9545/F12 capsule; or test: GDC-9545/F12 
capsule, reference: GDC-9545 Solution for Infusion; or test: GDC-9545/F18 capsule, 
reference: GDC-9545 Solution for Infusion). 
6.6 
METABOLITE PROFILING AND IDENTIFICATION ANALYSES 
Metabolite profiling of plasma, urine and feces will be performed using liquid 
chromatography-high resolution mass spectrometry where appropriate.  
These aspects will be reported separately from the Clinical Study Report as a 
standalone document. 
6.7 
SAFETY ANALYSES 
The safety analysis population will consist of all subjects who received at least one dose 
of study drug, with subjects grouped according to treatment received.  
All verbatim adverse event terms will be mapped to Medical Dictionary for Regulatory 
Activities (MedDRA) thesaurus terms, and adverse event severity will be graded from 1 
to 5 based on the adverse event severity grading scale for the NCI CTCAE (see 
Section 5.3.3). Adverse events of special interest will also be collected and reported (see 
Section 5.4.2). 

 
GDC-9545—Genentech, Inc. 
77/Protocol GP42662 (QSC204283), Version 4 
Summary tables will be presented by treatment.  If a subject has more than one episode 
of a particular event, only one episode (the most severe or the strongest causal 
relationship to study drug) will be counted.  A subject with more than one different 
adverse event within a particular body system will only be counted once in the total 
number of subjects experiencing adverse events for the body system.  Similarly, a 
subject who experiences an adverse event in more than one body system will only be 
counted once in the total number of subjects experiencing adverse events in all body 
systems.  
Selected laboratory and vital sign anomalies will be presented by shift tables and will be 
listed. 
6.8 
INTERIM ANALYSES 
6.8.1 
Planned Interim Analysis 
Part 1 and Part 2 will be analyzed separately. 
No interim analyses are planned for Part 1.  
The following in-study decision will be made during Part 2 of this study: 
• 
Progression from sentinel group to main group where sentinel dosing is used for 
Treatment B 
For Treatment B, to assess tolerability of the IV administration, the first subject will be 
dosed as a sentinel; then, at least 4 hours later, the second subject will be dosed only if 
there are no acute safety findings for the first subject. If the first two subjects tolerated 
the IV dose, in the opinion of the Principal Investigator and Medical Monitor, the 
remaining subjects will be dosed. The third subject will be dosed at least 20 hours after 
the second subject (i.e., at least 24 hours after the first subject). All subsequent dosing 
of the IV formulation will be staggered by at least 15 minutes. 
The decision to proceed with the main group will be made by the Investigator, based on 
safety data until up to 24 hours post-dose for the two sentinel subjects.  The Investigator 
will inform the sponsor of any safety concerns.  
The decision to proceed to the next dose level will be based on safety and tolerability 
data.  The following data are required: 
• 
Adverse events 
• 
ECGs 
• 
Vital signs  

 
GDC-9545—Genentech, Inc. 
78/Protocol GP42662 (QSC204283), Version 4 
7. 
DATA COLLECTION AND MANAGEMENT 
7.1 
DATA QUALITY ASSURANCE 
A contract research organization (CRO) will be responsible for data management of this 
study, including quality checking of the data.  The CRO will supply eCRF specifications 
for this study.  Data entered manually will be collected via EDC through use of eCRFs.  
The site will be responsible for data entry into the EDC system.  In the event of 
discrepant data, the CRO’s Data Management department will request data clarification 
from the site, which Data Management will resolve electronically in the EDC system. 
The CRO will produce a Data Management Plan that describes the quality checking to 
be performed on the data.  Laboratory data will be sent directly to the CRO, using the 
CRO’s standard procedures to handle and process the electronic transfer of these data. 
The Sponsor will perform oversight of the data management of this study, including 
approval of the CRO's Data Management Plans and specifications.  Data will be 
periodically transferred electronically from the CRO to the Sponsor, and the Sponsor's 
standard procedures will be used to handle and process the electronic transfer of these 
data.   
eCRFs and correction documentation will be maintained in the EDC system's audit trail.  
System backups for data stored at the CRO and records retention for the study data will 
be consistent with the CRO's standard procedures.  
AEs, medical histories and medications will be coded as detailed in the Data 
Management Plan.  An independent coding review will also be performed within the Data 
Sciences department. 
7.2 
ELECTRONIC CASE REPORT FORMS  
eCRFs are to be completed through use of a Sponsor-designated EDC system.  The site 
will receive training for appropriate eCRF completion.  eCRFs will be submitted 
electronically to the Sponsor and should be handled in accordance with instructions from 
the Sponsor. 
All eCRFs should be completed by designated, trained site staff.  eCRFs should be 
reviewed and electronically signed and dated by the Investigator or a designee. 
At the end of the study, the Investigator will receive subject data for his or her site in a 
readable format that must be kept with the study records.  Acknowledgement of receipt 
of the data is required. 

 
GDC-9545—Genentech, Inc. 
79/Protocol GP42662 (QSC204283), Version 4 
7.3 
SOURCE DATA DOCUMENTATION 
Study monitors will perform ongoing source data verification and review to confirm that 
critical protocol data (i.e., source data) entered into the eCRFs by authorized site 
personnel are accurate, complete, and verifiable from source documents.  
Source documents (paper or electronic) are those in which subject data are recorded 
and documented for the first time.  They include, but are not limited to, hospital records, 
clinical and office charts, laboratory notes, memoranda, evaluation checklists, pharmacy 
dispensing records, recorded data from automated instruments, copies of transcriptions 
that are certified after verification as being accurate and complete, microfiche, 
photographic negatives, microfilm or magnetic media, X-rays, subject files, and records 
kept at pharmacies, laboratories, and medico-technical departments involved in a clinical 
trial. 
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data. 
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section 7.5. 
To facilitate source data verification and review, the Investigators and institutions must 
provide the Sponsor direct access to applicable source documents and reports for 
trial-related monitoring, Sponsor audits, and EC review.  The study site must also allow 
inspection by applicable health authorities. 
7.4 
USE OF COMPUTERIZED SYSTEMS 
When clinical observations are entered directly into a study site's computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computerized systems used in clinical research.  An 
acceptable computerized data collection system allows preservation of the original entry 
of data.  If original data are modified, the system should maintain a viewable audit trail 
that shows the original data as well as the reason for the change, name of the person 
making the change, and date of the change. 
7.5 
RETENTION OF RECORDS 
Records and documents pertaining to the conduct of this study and the distribution of 
IMP, including eCRFs, , Informed Consent Forms, laboratory test results, and 
medication inventory records, must be retained by the Principal Investigator for 15 years 
after completion or discontinuation of the study or for the length of time required by 

 
GDC-9545—Genentech, Inc. 
80/Protocol GP42662 (QSC204283), Version 4 
relevant national or local health authorities, whichever is longer.  After that period of 
time, the documents may be destroyed, subject to local regulations.   
No records may be disposed of without the written approval of the Sponsor.  Written 
notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location. 
Roche will retain study data for 25 years after the final study results have been reported 
or for the length of time required by relevant national or local health authorities, 
whichever is longer. 
8. 
ETHICAL CONSIDERATIONS 
8.1 
COMPLIANCE WITH LAWS AND REGULATIONS 
This study will be conducted in full conformance with the ICH E6 guideline for GCP and 
the principles of the Declaration of Helsinki, or the applicable laws and regulations of the 
country in which the research is conducted, whichever affords the greater protection to 
the individual.  The study will comply with the requirements of the ICH E2A guideline 
(Clinical Safety Data Management:  Definitions and Standards for Expedited Reporting).  
Studies conducted in the United States or under a U.S. Investigational New Drug (IND) 
Application will comply with U.S. FDA regulations and applicable local, state, and federal 
laws.  Studies conducted in the European Union or European Economic Area will comply 
with the E.U.  Clinical Trial Directive (2001/20/EC) and applicable local, regional, and 
national laws. 
8.2 
INFORMED CONSENT 
The Sponsor's sample Informed Consent Form (and ancillary sample Informed Consent 
Forms such as an Assent Form or Mobile Nursing Informed Consent Form, if applicable) 
will be provided to each site.  If applicable, it will be provided in a certified translation of 
the local language.  The Sponsor or its designee must review and approve any proposed 
deviations from the Sponsor's sample Informed Consent Forms or any alternate consent 
forms proposed by the site (collectively, the "Consent Forms") before EC submission.  
The final EC−approved Consent Forms must be provided to the Sponsor for health 
authority submission purposes according to local requirements. 
If applicable, the Informed Consent Form will contain separate sections for any optional 
procedures.  The Investigator or authorized designee will explain to each subject the 
objectives, methods, and potential risks associated with each optional procedure.  
Subjects will be told that they are free to refuse to participate and may withdraw their 
consent at any time for any reason.  A separate, specific signature will be required to 
document a subject's agreement to participate in optional procedures.  Subjects who 
decline to participate will not provide a separate signature. 

 
GDC-9545—Genentech, Inc. 
81/Protocol GP42662 (QSC204283), Version 4 
The Consent Forms must be signed and dated by the subject or the subject's legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each subject shall document the informed consent process and that 
written informed consent was obtained prior to participation in the study. 
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the 
subject to participate.  The final revised EC-approved Consent Forms must be provided 
to the Sponsor for health authority submission purposes. 
If the Consent Forms are revised (through an amendment or an addendum) while a 
subject is participating in the study, the subject or a legally authorized representative 
must re-consent by signing the most current version of the Consent Forms or the 
addendum, in accordance with applicable laws and EC policy.  For any updated or 
revised Consent Forms, the case history or clinical records for each subject shall 
document the informed consent process and that written informed consent was obtained 
using the updated/revised Consent Forms for continued participation in the study. 
A copy of each signed Consent Form must be provided to the subject or the subject's 
legally authorized representative.  All signed and dated Consent Forms must remain in 
each subject's study file or in the site file and must be available for verification by study 
monitors at any time. 
8.3 
ETHICS COMMITTEE 
This protocol, the Informed Consent Forms, any information to be given to the subject, 
and relevant supporting information must be submitted to the EC by the Principal 
Investigator and reviewed and approved by the EC before the study is initiated.  
In addition, any subject recruitment materials must be approved by the EC.  
The Principal Investigator is responsible for providing written summaries of the status of 
the study to the EC annually or more frequently in accordance with the requirements, 
policies, and procedures established by the EC.  Investigators are also responsible for 
promptly informing the EC of any protocol amendments (see Section 9.6). 
In addition to the requirements for reporting all adverse events to the Sponsor, 
Investigators must comply with requirements for reporting serious adverse events to the 
local health authority and EC.  Investigators may receive written IND safety reports or 
other safety-related communications from the Sponsor.  Investigators are responsible for 
ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by their EC and 
archived in the site's study file.  

 
GDC-9545—Genentech, Inc. 
82/Protocol GP42662 (QSC204283), Version 4 
8.4 
ADMINISTRATION OF RADIATION 
Dr 
 will be the ARSAC Practitioner for this study, which includes the 
administration of radiation at Quotient Sciences.  Administration will be conducted in 
accordance with Dr 
’s current ARSAC Practitioner license and Quotient Sciences’ 
current ARSAC Employer license.  Additionally, a research application will be submitted 
to ARSAC to obtain approval for the conduct of the study before dosing. 
The protocol will be reviewed and the final version will be approved by the ARSAC 
Practitioner, Dr 
. 
8.5 
CONFIDENTIALITY 
The Sponsor maintains confidentiality standards by coding each subject enrolled in the 
study through assignment of a unique subject identification number.  This means that 
subject names are not included in data sets that are transmitted to any Sponsor location. 
Subject medical information obtained by this study is confidential and may be disclosed 
to third parties only as permitted by the Informed Consent Form (or separate 
authorization for use and disclosure of personal health information) signed by the 
subject, unless permitted or required by law. 
Medical information may be given to a subject's personal physician or other appropriate 
medical personnel responsible for the subject's welfare, for treatment purposes. 
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study Investigators or 
subjects unless required by law.  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication 
(see Section 9.5). 
Data generated by this study must be available for inspection upon request by 
representatives of national and local health authorities; Sponsor monitors, 
representatives, and collaborators; and the EC for each study site, as appropriate. 
Study data may be submitted to government or other health research databases or 
shared with researchers, government agencies, companies, or other groups that are not 
participating in this study.  These data may be combined with or linked to other data and 
used for research purposes, to advance science and public health, or for analysis, 
development, and commercialization of products to treat and diagnose disease.  In 
addition, redacted Clinical Study Reports and other summary reports will be provided 
upon request (see Section 9.5). 
8.6 
FINANCIAL DISCLOSURE 
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 

 
GDC-9545—Genentech, Inc. 
83/Protocol GP42662 (QSC204283), Version 4 
financial certification or disclosure statements to the appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study (see definition of end of 
study in Section 3.2). 
9. 
STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION 
9.1 
STUDY DOCUMENTATION 
The Investigator must maintain adequate and accurate records to enable the conduct of 
the study to be fully documented, including, but not limited to, the protocol, protocol 
amendments, Informed Consent Forms, and documentation of EC and governmental 
approval.  In addition, at the end of the study, the Investigator will receive the subject 
data, including an audit trail containing a complete record of all changes to data. 
9.2 
PROTOCOL DEVIATIONS 
The Investigator should document and explain any protocol deviations.  The Investigator 
should promptly report any deviations that might have an impact on subject safety and 
data integrity to the Sponsor and to the EC in accordance with established EC policies 
and procedures.  The Sponsor will review all protocol deviations and assess whether 
any represent a serious breach of GCP guidelines and require reporting to health 
authorities.  As per the Sponsor's standard operating procedures, prospective requests 
to deviate from the protocol, including requests to waive protocol eligibility criteria, are 
not allowed. 
9.3 
SITE INSPECTIONS 
Site visits will be conducted by the Sponsor or an authorized representative for 
inspection of study data, subjects' medical records, and eCRFs.  The Investigator will 
permit national and local health authorities; Sponsor monitors, representatives, and 
collaborators; and the ECs to inspect facilities and records relevant to this study. 
9.4 
ADMINISTRATIVE STRUCTURE 
This trial will be sponsored and managed by Genentech, Inc. 
The study will be conducted at a single-center: Quotient Sciences, Mere Way, 
Ruddington Fields, Ruddington, Nottingham, NG11 6JS, UK. 
Central facilities will be used for certain study assessments throughout the study (e.g., 
clinical laboratory tests, PK analyses and metabolite profiling and identification) as 
specified in Section 4.5. 
Monitoring will be performed by
 Wirral Clinical Consultancy Ltd, 76 Pipers 
Lane, Lower Heswall Wirral, Cheshire, CH60 9HN, UK. 

 
GDC-9545—Genentech, Inc. 
84/Protocol GP42662 (QSC204283), Version 4 
The ARSAC Practitioner will be 
MB BChir, MRCGP, MFPM, Tel: 
 email:
9.5 
DISSEMINATION OF DATA AND PROTECTION OF TRADE 
SECRETS 
Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing 
information on the trial to healthcare professionals and to the public, at scientific 
congresses, in clinical trial registries, and in peer-reviewed journals.  The Sponsor will 
comply with all requirements for publication of study results.  Study data may be shared 
with others who are not participating in this study (see Section 8.5 for details), and 
redacted Clinical Study Reports and other summary reports will be made available upon 
request.  For more information, refer to the Roche Global Policy on Sharing of Clinical 
Trials Data at the following website: 
www.roche.com/roche global policy on sharing of clinical study information.pdf 
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in subjects involving an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within 6 months after the availability of 
the respective Clinical Study Report.  In addition, for all clinical trials in subjects involving 
an IMP for which a marketing authorization application has been filed or approved in any 
country, the Sponsor aims to publish results from analyses of additional endpoints and 
exploratory data that are clinically meaningful and statistically sound. 
The Investigator must agree to submit all manuscripts or abstracts to the Sponsor prior 
to submission for publication or presentation.  This allows the Sponsor to protect 
proprietary information and to provide comments based on information from other 
studies that may not yet be available to the Investigator. 
In accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter trials only in their entirety and not as individual center 
data.  In this case, a coordinating Investigator will be designated by mutual agreement. 
Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by the Investigator and the 
appropriate Sponsor personnel. 
Any inventions and resulting patents, improvements, and/or know-how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise. 

 
GDC-9545—Genentech, Inc. 
85/Protocol GP42662 (QSC204283), Version 4 
9.6 
PROTOCOL AMENDMENTS 
Any protocol amendments will be prepared by the Sponsor.  Protocol amendments will 
be submitted to the EC and to regulatory authorities in accordance with local regulatory 
requirements. 
Approval must be obtained from the EC and regulatory authorities (as locally required) 
before implementation of any substantial changes, except for changes necessary to 
eliminate an immediate hazard to subjects or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact information). 
Any amendments relating to the administration of radioactive substances will be 
reviewed by the ARSAC Practitioner prior to submission to ARSAC as required by the 
current ARSAC Notes for Guidance.  The ARSAC Practitioner will also be notified of any 
substantial amendments to the PIS and ICF and/or protocol. 

 
GDC-9545—Genentech, Inc. 
86/Protocol GP42662 (QSC204283), Version 4 
10. 
REFERENCES 
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN 
estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 
Cancer J Clin 2018;68(6):394−424. 
FDA Guidance: Food effect bioavailability and fed bioequivalence studies. 2002. 
EMA – Guidance on the investigation of bioequivalence. 20 Jan 2010. 
Health and Safety. Ionising Radiation (Medical Exposure) Regulations 2017. Statutory 
Instrument 2017 No. 1322. 
Ionising Radiation Exposure of the UK population: 2010 Review. Public Health England. 
Apr 2016. https://www.gov.uk/government/publications/ionising-radiation-
exposure-of-the-uk-population-2010-review 
Notes for guidance on the clinical administration of radiopharmaceuticals and use of 
sealed radioactive sources. Administration of Radioactive Substances Advisory 
Committee. Sep 2020. 
RO7197597 (GDC-9545) Investigator’s Brochure. F. Hoffmann-La Roche Ltd. Version 4, 
May 2020. 
 
 
 

 
GDC-9545—Genentech, Inc. 
87/Protocol GP42662 (QSC204283), Version 4 
Appendix 1  
Part 1 Schedule of Activities 
Study Procedures 
Screening 
Residency in Clinical Unit 
Days 
–28 to –2 
–1a 
1 
2 
3 
4 
5 
6 
Time after study drug dosing 
(hours) b 
 
 
Pre-
dose 
0 
1 
1.5 
2 
2.5 
3 
4 
5 
6 
8 
12 24 48 72 96 120
Informed consent 
Xc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion criteria 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history  
X 
Xd 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete physical examination e 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Limited physical examination f 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Height, weight and BMI 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vein assessment 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12-lead safety ECG 
X 
 
X 
 
X 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
Vital signs g 
X 
 
X 
 
X 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
Laboratory safety tests h 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urinalysis i 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine drug screen j 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alcohol breath test 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carbon monoxide breath test 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Virology screen k 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Estradiol and FSH l 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnancy test m 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Appendix 1: Part 1 Schedule of Activities 
  
GDC-9545—Genentech, Inc. 
88/Protocol GP42662 (QSC204283), Version 4 
Study Procedures 
Screening 
Residency in Clinical Unit 
Days 
–28 to –2 
–1a 
1 
2 
3 
4 
5 
6 
Time after study drug dosing 
(hours) b 
 
 
Pre-
dose 
0 
1 
1.5 
2 
2.5 
3 
4 
5 
6 
8 
12 24 48 72 96 120
Adverse event monitoring n 
 
Prior and concomitant medications o 
 
Study drug administration 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma samples for GDC-9545 and 
total radioactivity PK p 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X X X X X 
Whole blood samples for total 
radioactivity PK p 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X X X X X 
Plasma samples for metabolite 
profiling and ID p 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X X X X X 
Urine samples for total radioactivity 
and metabolite profiling and 
identification q 
 
 
 
Feces samples for total radioactivity 
and metabolite profiling and 
identification r 
 
 
Confinement in the clinic 
 
 
 

Appendix 1: Part 1 Schedule of Activities 
  
GDC-9545—Genentech, Inc. 
89/Protocol GP42662 (QSC204283), Version 4 
Study Procedures 
Residency in Clinical Unit 
Return Visits 
Days 7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21s 
28s 
35s 
42s 
Time after study drug dosing 
(hours) b 144 168 
192 
216 
240 
264 
288 
312 
336 
360 
384 
408 
432 
456 
480 648 816 984 
Limited physical examination f 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
12-lead safety ECG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
Vital signs g 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
Laboratory safety tests h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
Urinalysis i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
Adverse event monitoring n 
 
Prior and concomitant medications 
o 
 
Plasma samples for GDC-9545 
and total radioactivity PK p 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Whole blood samples for total 
radioactivity PK p 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Plasma samples for metabolite 
profiling and ID p 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urine samples for total radioactivity 
and metabolite profiling and 
identification q 
 
X 
X 
X 
Feces samples for total 
radioactivity and metabolite 
profiling and identification r 
 
X 
X 
X 
Confinement in the clinic 
 
X 
X 
X 

Appendix 1: Part 1 Schedule of Activities 
  
GDC-9545—Genentech, Inc. 
90/Protocol GP42662 (QSC204283), Version 4 
Study Procedures 
Residency in Clinical Unit 
Return Visit 
Days 7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21s 
28s 
35s 
42s 
Time after study drug dosing 
(hours) b 144 168 
192 
216 
240 
264 
288 
312 
336 
360 
384 
408 
432 
456 
480 648 816 984 
Return visits 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
X 
a Admission to the clinical unit.  Eligibility will be reassessed at admission/pre-dose. 
b All assessments will be timed and performed relative to the start of dosing 
c Informed consent must be documented before any study-specific screening procedure is performed, and may be obtained more than 28 days 
before initiation of study treatment. 
d Update only 
e Includes evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatologic, musculoskeletal, respiratory, GI, 
genitourinary, and neurologic systems. 
f Perform a limited, symptom-directed examination at specified timepoints or as clinically indicated. 
g Includes pulse rate, and systolic and diastolic blood pressure while the subject is in a supine position, and oral temperature at all time points. 
h Hematology includes white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin, hematocrit (packed cell volume), mean cell 
hemoglobin, mean cell hemoglobin concentration, mean cell volume, platelet count, and differential count (neutrophils, eosinophils, basophils, 
monocytes, lymphocytes).  Chemistry panel (serum) includes magnesium, sodium, potassium, chloride, glucose, fasting glucose, urea, 
creatinine, creatine kinase, total protein, albumin, phosphate (inorganic), calcium, total bilirubin, direct bilirubin (only if total is elevated), alkaline 
phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), and bicarbonate.  
Creatinine clearance will be estimated at screening from serum creatinine using the Cockcroft-Gault equation for eligibility purposes.  
Coagulation panel includes international normalized ratio (INR), activated partial thromboplastin time (APTT), thrombin time and prothrombin 
time (PT). 
i Includes pH, specific gravity, glucose, protein, ketones, blood, bilirubin, leukocytes, nitrites, urobilinogen. Microbiology and/or microscopic 
urinalysis examination, at the discretion of the Investigator based on urinalysis results (sediment, RBCs, WBCs, casts, crystals, epithelial cells, 
bacteria). 
j Amphetamines, barbiturates, benzodiazepines, cocaine, marijuana/cannabis, methadone, methamphetamine/ecstasy, morphine/opiates, 
phencyclidine, and tricyclic anti-depressants. 
k HBsAg, HCV Antibody, HIV Antibody for all subjects. 
l Estradiol and FSH for post-menopausal female subjects only. 

Appendix 1: Part 1 Schedule of Activities 
  
GDC-9545—Genentech, Inc. 
91/Protocol GP42662 (QSC204283), Version 4 
m All subjects must have a negative highly sensitive serum pregnancy test result at screening and a negative highly sensitive urine pregnancy test 
at admission. 
n After informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protocol-mandated 
intervention should be reported.  After initiation of study drug, all adverse events will be reported until 28 days after the final dose of study drug.  
All deaths that occur during the protocol-specified adverse event reporting period (see Section 5.3.1), regardless of relationship to study drug, 
must be recorded on the Adverse Event eCRF and immediately reported to the Sponsor (see Section 5.4.2).  Deaths that occur after the 
adverse event reporting period should be reported as described in Section 5.6.  In addition, the Sponsor should be notified if the Investigator 
becomes aware of any serious adverse event that is believed to be related to prior study drug treatment (see Section 5.6). 
o Medication (e.g., prescription drugs, over-the-counter drugs, HRT, vaccines, topical medications, herbal or homeopathic remedies, nutritional 
supplements) used by a subject in addition to protocol-mandated treatment from 14 days prior to initiation of study drug until discharge from the 
study. 
p See Appendix 3 for detailed schedule.  Blood sample collection will be at pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours post-dose, and at 
24-hour intervals thereafter until study completion (including after discharge, if needed)/early termination.  Permissible time windows for PK 
sampling are: pre-dose, ≤1 hour before dosing; 1 hour post-dose, ±5 minutes; 1.5 to 8 hours, ±15 minutes; 12 to 24 hours, ±30 minutes; 48 to 
480 hours, ±4 hours; 648 to 984 hours, ±1 day 
q A single urine sample will be collected at pre-dose (the first void of the day) and then at the following collection periods: 0 to 12 hours, 12 to 24 
hours, and then daily (24 hour intervals) until the mass balance discharge criteria have been met or until Day 21, and then on a weekly basis 
starting on Day 28 (until criteria met or Day 42 reached). 
r The pre-dose feces sample will be taken in the 24 hours period before dosing (between admission and pre-dose).  Post-dose feces will be 
collected at 24 hour intervals until the mass balance discharge criteria have been met or until Day 21, and then on a weekly basis starting on 
Day 28 (until criteria met or Day 42 reached). 
s It is planned that subjects will remain resident in the clinical unit until 480 hours post-dose (Day 21) when they will be discharged from the 
clinical unit.  The same procedures are to be performed at early termination/withdrawal as at discharge.  Subjects may be discharged as a 
group earlier if the mass balance discharge criteria have been achieved.  If the criteria have not been met by Day 21, subjects will be 
discharged from the clinical unit and those who have not met the discharge criteria will return for outpatient visits every 7 days for a 24-hour 
sample collection interval until the mass balance discharge criteria are met (the maximum number of 24-hour return visits will not exceed 3).  
Discharged subjects may be asked to return for these visits if samples are needed post-discharge, prior to study completion.  If additional 
residency is not considered appropriate or necessary, then home collections of urine and/or feces may be requested at the discretion of the 
Investigator for individual subjects.  Safety discharge assessments will be performed at the time of actual discharge or early 
termination/withdrawal from the clinical unit.  PK, TR and metabolite profiling and identification blood samples to be collected at 480 hours 
post-dose or at time of actual discharge/early termination if earlier.  Any subject who discontinues or is withdrawn from the study after being 
discharged from the clinical unit will be asked to return to the clinical unit to undergo early termination/withdrawal procedures. 

 
GDC-9545—Genentech, Inc. 
92/Protocol GP42662 (QSC204283), Version 4 
Appendix 2  
Part 2 Schedule of Activities 
Study Procedures 
Screening  
Study days in each period 
 
–28 to –2 
-1a 
1 
2 
Time after study drug dosing (hours) 
– (relative to start of IV infusion for 
Treatment B) b 
 
 
Pre-
dose 
0 0.25 0.5 0.58 0.67 1 
1.5 
2 
2.5 
3 
4 
5 
6 
8 
12 24 
Informed consent 
Xc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion criteria 
X 
Xd 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history  
X 
Xe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete physical examination f 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Limited physical examination g 
 
Xh 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Height, weight and BMI 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vein assessment 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12-lead safety ECG 
X 
 
X 
 
 
X 
 
 
X 
 
 
 
 
X 
 
 
 
 
X 
Vital signs i 
X 
 
X 
 
 
X 
 
 
X 
 
 
 
 
X 
 
 
 
 
X 
Laboratory safety tests j 
X 
Xh 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urinalysis k 
X 
Xh 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine drug screen l 
X 
Xd 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alcohol breath test 
X 
Xd 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carbon monoxide breath test 
X 
Xd 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomization  
 
 
Xd 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Virology screen m 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Estradiol and FSH n 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnancy test o 
X 
Xd 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Appendix 2: Part 2 Schedule of Activities  
  
GDC-9545—Genentech, Inc. 
93/Protocol GP42662 (QSC204283), Version 4 
Study Procedures 
Screening  
Study days in each period 
 
–28 to –2 
-1a 
1 
2 
Time after study drug dosing (hours) 
– (relative to start of IV infusion for 
Treatment B) b 
 
 
Pre-
dose 
0 0.25 0.5 0.58 0.67 1 
1.5 
2 
2.5 
3 
4 
5 
6 
8 
12 24 
Adverse event monitoring p 
 
Prior and concomitant medications q 
 
Study drug administration r 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma samples for GDC-9545 PK s 
 
 
X 
 
Xt 
Xt 
Xt 
Xt 
X 
X 
X 
Xu 
X 
X 
Xu 
X 
X 
X 
X 
Confinement in the clinic 
 
 
 
 
 
 
 
 
 
 

Appendix 2: Part 2 Schedule of Activities  
  
GDC-9545—Genentech, Inc. 
94/Protocol GP42662 (QSC204283), Version 4 
Study Procedures 
Study days in each period 
Follow-Up 
Phone Call 
 
3 
4 
5 
6 
7 
8v 
14 to 16w 
Time after study drug dosing 
(hours) – (relative to start of IV 
infusion for Treatment B) b 
48 
72 
96 
120 
144 
168 
 
Limited physical examination g 
 
 
 
 
 
Xx 
 
12-lead safety ECG 
 
 
 
 
 
Xx 
 
Vital signs i 
 
 
 
 
 
Xx 
 
Laboratory safety tests j 
 
 
 
 
 
Xx 
 
Urinalysis k 
 
 
 
 
 
Xx 
 
Adverse event monitoring p 
 
Prior and concomitant medications 
q 
 
Plasma samples for GDC-9545 PK 
s 
X 
X 
X 
X 
X 
Xy 
 
Confinement in the clinic 
 
 
0.25 hours = 15 minutes, 0.5 hours = 30 minutes, 0.58 hours = 35 minutes; 0.67 hours = 40 minutes 
a Admission to the clinical unit (Period 1 only).  Subjects will be resident in the clinical unit for 28 to 29 consecutive nights that will cover all 
3 treatment periods. Eligibility will be reassessed at admission/pre-dose. 
b All assessments will be timed and performed relative to the start of dosing 
c Informed consent must be documented before any study-specific screening procedure is performed, and may be obtained more than 28 days 
before initiation of study treatment. 
d Period 1 only 
e Update only (Period 1 only). 

Appendix 2: Part 2 Schedule of Activities  
  
GDC-9545—Genentech, Inc. 
95/Protocol GP42662 (QSC204283), Version 4 
f Includes evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatologic, musculoskeletal, respiratory, GI, 
genitourinary, and neurologic systems. 
g Perform a limited, symptom-directed examination at specified timepoints or as clinically indicated. 
h Periods 1, 2 and 3 
i Includes pulse rate, and systolic and diastolic blood pressure while the subject is in a supine position, and oral temperature at all time points. 
j Hematology includes white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin, hematocrit (packed cell volume), mean cell 
hemoglobin, mean cell hemoglobin concentration, mean cell volume, platelet count, and differential count (neutrophils, eosinophils, basophils, 
monocytes, lymphocytes).  Chemistry panel (serum) includes magnesium, sodium, potassium, chloride, glucose, fasting glucose, urea, 
creatinine, creatine kinase, total protein, albumin, phosphate (inorganic), calcium, total bilirubin, direct bilirubin (only if total is elevated), alkaline 
phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), and bicarbonate.  
Creatinine clearance will be estimated at screening from serum creatinine using the Cockcroft-Gault equation for eligibility purposes.  
Coagulation panel includes international normalized ratio (INR), activated partial thromboplastin time (APTT), thrombin time and prothrombin 
time (PT). 
k Includes pH, specific gravity, glucose, protein, ketones, blood, bilirubin, leukocytes, nitrites, urobilinogen. Microbiology and/or microscopic 
urinalysis examination, at the discretion of the Investigator based on urinalysis results (sediment, RBCs, WBCs, casts, crystals, epithelial cells, 
bacteria). 
l Amphetamines, barbiturates, benzodiazepines, cocaine, marijuana/cannabis, methadone, methamphetamine/ecstasy, morphine/opiates, 
phencyclidine, and tricyclic anti-depressants. 
m HBsAg, HCV Antibody, HIV Antibody for all subjects. 
n Estradiol and FSH for post-menopausal female subjects only. 
o All subjects must have a negative highly sensitive serum pregnancy test result at screening and a negative highly sensitive urine pregnancy test 
at admission. 
p After informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protocol-mandated 
intervention should be reported.  After initiation of study drug, all adverse events will be reported until 28 days after the final dose of study drug.  
All deaths that occur during the protocol-specified adverse event reporting period (see Section 5.3.1), regardless of relationship to study drug, 
must be recorded on the Adverse Event eCRF and immediately reported to the Sponsor (see Section 5.4.2).  Deaths that occur after the 
adverse event reporting period should be reported as described in Section 5.6.  In addition, the Sponsor should be notified if the Investigator 
becomes aware of any serious adverse event that is believed to be related to prior study drug treatment (see Section 5.6). 
q Medication (e.g., prescription drugs, over-the-counter drugs, HRT, vaccines, topical medications, herbal or homeopathic remedies, nutritional 
supplements) used by a subject in addition to protocol-mandated treatment from 14 days prior to initiation of study drug until discharge from the 
study. 

Appendix 2: Part 2 Schedule of Activities  
  
GDC-9545—Genentech, Inc. 
96/Protocol GP42662 (QSC204283), Version 4 
r Treatment B will be administered intravenously over 30 minutes (as an infusion). For Treatment B only, to assess tolerability of the IV 
administration, the first subject will be dosed as a sentinel; then, at least 4 hours later, the second subject will be dosed only if there are no 
acute safety findings for the first subject. If the first two subjects tolerated the IV dose, in the opinion of the Principal Investigator and Medical 
Monitor, the remaining subjects will be dosed. The third subject will be dosed at least 20 hours after the second subject (i.e., at least 24 hours 
after the first subject). All subsequent dosing of the IV formulation will be staggered by at least 15 minutes. For Treatments C and D, all subjects 
will be dosed as a single cohort. 
s See Appendix 4 for detailed schedule.  Permissible time windows for PK sampling and other assessments are: pre-dose, ≤1 hour before dosing; 
0.25 to 0.5 hours post-dose, ±2 minutes; 0.58 to 1 hour, ±5 minutes; 1.5 to 8 hours, ±15 minutes; 12 to 24 hours, ±30 minutes; 48 to 168 hours, 
±4 hours. 
t Treatment B (IV dose only). 0.5 hours sample to be taken immediately after IV administration (i.e., 30 minutes after the start of the IV 
administration) 
u Treatments C and D (oral doses) only. 
v Discharge from clinical unit in Period 3 only.  The same procedures are to be performed at early termination/withdrawal as at discharge. 
w Follow-up telephone call at 13 to 15 days post-final dose. 
x Period 3 only; safety discharge assessments will be performed at the time of actual discharge/early termination from the clinical unit 
y Periods 1, 2 and 3. In Period 3, PK blood samples to be collected at 168 hours post-dose or at time of actual discharge/early termination if 
earlier. 
 
 

 
GDC-9545—Genentech, Inc. 
97/Protocol GP42662 (QSC204283), Version 4 
Appendix 3  
Part 1 Schedule of Pharmacokinetic Samples 
Visit a 
Time point a 
Sample Type 
Day 1 
Pre-dose 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
0 to 12.0 hours 
post-dose 
Urine (total radioactivity and metabolite profiling and 
identification)b 
0 to 24.0 hours  
Feces (total radioactivity and metabolite profiling and 
identification)c 
1.0 hour  
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
1.5 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
2.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
2.5 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
3.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
4.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
5.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
6.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
8.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 

Appendix 3  
Part 1 Schedule of Pharmacokinetic Assessments  
GDC-9545—Genentech, Inc. 
98/Protocol GP42662 (QSC204283), Version 4 
Visit a 
Time point a 
Sample Type 
Day 1 
12.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
12.0 to 24.0 hours  
Urine (total radioactivity and metabolite profiling and 
identification)b 
Day 2 
24.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
24.0 to 48.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 3 
48.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
48.0 to 72.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 4 
72.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
72.0 to 96.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 5 
96.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
96.0 to 120.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 6 
120.0 hours  
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
120.0 to 144.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 

Appendix 3  
Part 1 Schedule of Pharmacokinetic Assessments  
GDC-9545—Genentech, Inc. 
99/Protocol GP42662 (QSC204283), Version 4 
Visit a 
Time point a 
Sample Type 
Day 7 
144.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
144.0 to 168.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 8 
168.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
168.0 to 192.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 9 
192.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
192.0 to 216.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 10 
216.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
261.0 to 240.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 11 
240.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
240.0 to 264.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 12  
264.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
264.0 to 288.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 

Appendix 3  
Part 1 Schedule of Pharmacokinetic Assessments  
GDC-9545—Genentech, Inc. 
100/Protocol GP42662 (QSC204283), Version 4 
Visit a 
Time point a 
Sample Type 
Day 12 
264.0 to 288.0 hours 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 13 
288.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
288.0 to 312.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 14 
312.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
312.0 to 336.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 15 
336.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
336.0 to 360.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 16 
360.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
360.0 to 384.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 17 
384.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
384.0 to 408.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 18 
408.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 

Appendix 3  
Part 1 Schedule of Pharmacokinetic Assessments  
GDC-9545—Genentech, Inc. 
101/Protocol GP42662 (QSC204283), Version 4 
Visit a 
Time point a 
Sample Type 
Day 18 
408.0 to 432.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 19 
432.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
432.0 to 456.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 20 
456.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
456.0 to 480.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 21 
480.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
Day 28 
648.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
648.0 to 672.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 35 
816.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
816.0 to 840.0 hours 
Urine (total radioactivity and metabolite profiling and 
identification)b 
Feces (total radioactivity and metabolite profiling and 
identification)c 
Day 42 
984.0 hours 
GDC-9545 and TR PK, and metabolite profiling and 
identification (plasma) 
TR PK (whole blood) 
984.0 to 1008.0 hours Urine (total radioactivity and metabolite profiling and 
identification)b 

Appendix 3  
Part 1 Schedule of Pharmacokinetic Assessments  
GDC-9545—Genentech, Inc. 
102/Protocol GP42662 (QSC204283), Version 4 
Visit a 
Time point a 
Sample Type 
Day 42 
984.0 to 1008.0 hours Feces (total radioactivity and metabolite profiling and 
identification)c 
PK = pharmacokinetic, TR = total radioactivity. 
a It is planned that subjects will be released as a group when all subjects have achieved the 
mass balance discharge criteria.  This may result in the subjects being discharged as a group 
prior to completion of the planned residency period.  Once the mass balance discharge 
criteria have been achieved, collection of all samples (blood, urine, and feces) may be 
stopped and the subjects will undergo discharge assessments.  Discharged subjects may be 
asked to return for these visits if samples are needed post-discharge, prior to study 
completion, if needed. 
Blood sample collection will be at pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours post-dose, 
and at 24-hour intervals thereafter until study completion (including after discharge, if 
needed)/early termination 
Permissible time windows for PK sampling are: pre-dose, ≤1 hour before dosing; 1 hour post-
dose, ±5 minutes; 1.5 to 8 hours, ±15 minutes; 12 to 24 hours, ±30 minutes; 48 to 480 hours, 
±4 hours; 648 to 984 hours, ±1 day 
b A single urine sample will be collected at pre-dose (the first void of the day) and then at the 
following collection periods: 0 to 12 hours, 12 to 24 hours, and then daily (24 hour intervals) 
until the mass balance discharge criteria have been met or until Day 21, and then on a weekly 
basis starting on Day 28 (until criteria met or Day 42 reached). 
c The pre-dose feces sample will be taken in the 24 hours period before dosing (between 
admission and pre-dose).  Post-dose feces will be collected at 24 hour intervals until the 
mass balance discharge criteria have been met or until Day 21, and then on a weekly basis 
starting on Day 28 (until criteria met or Day 42 reached). 
 
 

 
GDC-9545—Genentech, Inc. 
103/Protocol GP42662 (QSC204283), Version 4 
Appendix 4  
Part 2 Schedule of Pharmacokinetic Samples 
Visit a 
Time point a 
Sample Type 
Day 1 
Pre-dose 
GDC-9545 PK (plasma) 
0.25 hours post-dose b 
GDC-9545 PK (plasma) 
0.5 hours c 
GDC-9545 PK (plasma) 
0.58 hours d 
GDC-9545 PK (plasma) 
0.67 hours e 
GDC-9545 PK (plasma) 
1.0 hours 
GDC-9545 PK (plasma) 
1.5 hours 
GDC-9545 PK (plasma) 
2.0 hours 
GDC-9545 PK (plasma) 
2.5 hours f 
GDC-9545 PK (plasma) 
3.0 hours 
GDC-9545 PK (plasma) 
4.0 hours 
GDC-9545 PK (plasma) 
5.0 hours f 
GDC-9545 PK (plasma) 
6.0 hours 
GDC-9545 PK (plasma) 
8.0 hours 
GDC-9545 PK (plasma) 
12.0 hours 
GDC-9545 PK (plasma) 
Day 2 
24.0 hours 
GDC-9545 PK (plasma) 
Day 3 
48.0 hours 
GDC-9545 PK (plasma) 
Day 4 
72.0 hours 
GDC-9545 PK (plasma) 
Day 5 
96.0 hours 
GDC-9545 PK (plasma) 
Day 6 
120.0 hours 
GDC-9545 PK (plasma) 
Day 7 
144.0 hours 
GDC-9545 PK (plasma) 
Day 8 
168.0 hours 
GDC-9545 PK (plasma) 
PK = pharmacokinetic. 
a Visit and time points are applicable to all periods in Part 2, except where indicated.  For 
Treatment B (IV dose), time points are relative to the start of the IV administration. 
b 
 Treatment B (IV dose) only 
c Treatment B (IV dose only); sample to be taken immediately after IV administration (i.e., 
30 minutes after the start of the IV administration) 
d Treatment B (IV dose only); sample to be taken 5 minutes after the end of IV administration 
(i.e., 35 minutes after the start of the IV administration) 
e Treatment B (IV dose only); sample to be taken 10 minutes after the end of IV administration 
(i.e., 40 minutes after the start of the IV administration) 
f Treatments C and D (oral doses) only 
Permissible time windows for PK sampling and other assessments are: pre-dose, ≤1 hour 
before dosing; 0.25 to 0.5 hours post-dose, ±2 minutes; 0.58 to 1 hour, ±5 minutes; 1.5 to 
8 hours, ±15 minutes; 12 to 24 hours, ±30 minutes; 48 to 168 hours, ±4 hours